EP2575773A2

Synthetic nanocarrier combination vaccines

Abstract

This record has no abstract on file.

EP2575773A2, drawing sheet 1 — Sheet 1 of 6

Term

Projected expiry 26 May 2031.

61 claims: 27 independent, 34 dependent

1
Claims of equivalent WO 2011150264 A2 What is claimed is:1. A dosage form comprising: (1) a first population of synthetic nanocarriers that have one or more first antigens coupled to them, (
5
The dosage form of any of claims 2-4, wherein the one or more coupled adjuvants comprise an imidazoquinoline or oxoadenine.
7
The dosage form of any of claims 1-6, further comprising one or more adjuvants that are not coupled to the synthetic nanocarriers of the first population of synthetic nanocarriers.
10
The dosage form of any of claims 1-9, wherein the one or more first antigens are identical to the one or more second antigens.
11
The dosage form of any of claims 1-10, further comprising a second population of synthetic nanocarriers that have one or more third antigens coupled to them;wherein the first and third antigens are not identical.
12
The dosage form of any of claims 1-11, wherein the one or more first antigens comprise a B cell antigen or a T cell antigen.
14
The dosage form of any of claims 1-11, wherein the one or more first antigens comprise a B cell antigen or a T cell antigen and a T-helper cell antigen.
17
The composition of any of claims 13-16, wherein the T helper cell antigen is coupled by encapsulation.
18
The dosage form of any of claims 1-17, wherein the one or more second antigens comprise a B cell antigen or a T cell antigen.
19
The dosage form of any of claims 1-18, wherein the dosage form comprises a vaccine that comprises the second antigen that is not coupled to the synthetic nanocarriers.
22
The dosage form of any of claims 19-21, wherein the vaccine comprises BIOTHRAX, DAPTACEL, INFANRIX, TRIPEDIA, TRIHIBIT, KINRIX, PEDIARIX, PENTACEL, PEDVAXHIB, ACTHIB, HIBERIX, COMVAX, HAVRIX, VAQTA, ENGERIX-B, RECOMBIVAX HB, TWINRIX, ZOSTAVAX, GARDASIL, CERVARIX, FLUARIX, FLUVIRIN, FLUZONE, FLULAVAL, AFLURIA, AGRIFLU, FLUMIST, JE- VAX, IXIARO, M-M-R II, PROQUAD, MENOMUNE, MENACTRA, MENVEO, PNEUMOVAX 23, PREVNAR, PCV13, IPOL, IMOVAX RABIES, RABAVERT, ROTATEQ, ROTARIX, DECAVAC, BOOSTRIX, ADACEL, TYPHIM VI, VIVOTIF BERNA, VARIVAX, ACAM2000 or YF-VAX.
23
The dosage form of any of claims 1-21, wherein the one or more first antigens and/or one or more second antigens are obtained or derived from a virus of the Adenoviridae, Picornaviridae, Herpesviridae, Hepadnaviridae, Flaviviridae, Retroviridae, Orthomyxoviridae, Paramyxoviridae, Papillomaviridae, Rhabdoviridae, Togaviridae or Paroviridae family.
26
The dosage form of any of claims 1-21, wherein the one or more first antigens and/or one or more second antigens are obtained or derived from a bacteria of the Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia and Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema Vibrio or Yersinia genus.
29
The dosage form of any of claims 1-21, wherein the one or more first antigens and/or one or more second antigens are obtained or derived from a fungus of the Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocystis or Stachybotrys genus.
32
The dosage form of any of claims 1-21, wherein the one or more first antigens and/or one or more second antigens are obtained or derived from one or more proteins of human papilloma virus.
35
The dosage form of any of claims 1-21, wherein the one or more first antigens and/or one or more second antigens are obtained or derived from one or more proteins of hepatitis B virus.
38
The dosage form of any of claims 35-37, wherein when the one or more first antigens are obtained or derived from hepatitis B virus, the one or more second antigens are obtained or derived from one or more proteins of human papilloma virus.
39
The dosage form of any of claims 35-37, wherein when the one or more second antigens are obtained or derived from hepatitis B virus, the one or more first antigens are obtained or derived from one or more proteins of human papilloma virus.
41
The dosage form of any of claims 1-21, wherein the one or more first antigens and/or one or more second antigens are obtained or derived from one or more proteins of influenza virus.
44
The dosage form of claims 42, wherein the one or more first antigens are obtained or derived from hemagglutinin of H5N1 avian influenza virus, and the one or more second antigens are obtained or derived from M2 protein of influenza A virus.
47
The dosage form of any of claims 1-46, wherein the pharmaceutically acceptable excipient comprises a preservative, a buffer, saline, phosphate buffered saline, a colorant, or a stabilizer.
48
The dosage form of any of claims 1-47, wherein the first synthetic nanocarriers comprise lipid-based nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles, peptide or protein-based particles, lipid-polymer nanoparticles, spheroidal nanoparticles, cuboidal nanoparticles, pyramidal nanoparticles, oblong nanoparticles, cylindrical nanoparticles, or toroidal nanoparticles.
55
57. The method of claim 55, wherein the subject has or is at risk of having cancer.
56
58. The method of any of claims 55-57, wherein the dosage form is administered by oral, subcutaneous, pulmonary, intranasal, intradermal or intramuscular administration.
57
59. The dosage form of any one of claims 1-54 for use in therapy or prophylaxis.
58
60. The dosage form of any one of claims 1-54 for use in a method as defined in any one of claims 55-58.
59
61. The dosage form of any one of claims 1-54 for use in a method of treating or preventing cancer.
60
62. The dosage form of any one of claims 1-54 for use in a method of treating or preventing infection or infectious disease.
61
63. The dosage form of any one of claims 60-62, wherein the method comprises administration of the dosage form by oral, subcutaneous, pulmonary, intranasal, intradermal or intramuscular administration. 64. Use of the dosage form of any one of claims 1-54 for the manufacture of a medicament for use in a method as defined in any one of claims 55-58 or 60-63.

Independent claims29

388 paragraphs in 10 sections, as filed

Description of equivalent WO 2011150264 A2

SYNTHETIC NANOCARRIER COMBINATION VACCINES

0003This application claims the benefit under 35 U.S.C. §119 of United States provisional applications 61/348713, filed May 26, 2010, 61/348717, filed May 26, 2010, 61/348728, filed May 26, 2010, and 61/358635, filed June 25, 2010, the entire contents of each of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

0005To either minimize the number of childhood vaccinations and/or to provide broader immune protection against different strains of a given pathogen, there often is a desire to combine multiple antigens in a single dosage form, the resulting vaccine being termed a multivalent vaccine. The number of antigens that can be combined in a single dosage form may be limited by the amount of each antigen required to elicit the desired immune response and the aqueous solubility of the antigen.

0006At some point, the total liquid volume of the dosage form becomes too large to comfortably and/or safely administer the vaccine by an intramuscular and/or subcutaneous route. This limitation is especially noticeable in the case of multivalent conjugate vaccines such as Prevnar™, wherein each different oligosaccharide antigen is conjugated to a protein carrier (e.g., with 7 or 13 oligosaccharide antigens conjugated to CRM197, a non-toxic mutant of diphtheria toxin); or tetravalent Meningococcal vaccines wherein the antigens are also conjugated to CRM197 or other detoxified forms of diphtheria toxin.

0007Another limitation of existing vaccine formulations is their limited coverage or their physical incompatibility with one another which may preclude simple blending of two existing vaccines to create a new, combination vaccine. For example, vaccines can consist of virus like particles comprising one or more antigens which self assemble or are linked to self assembling proteins. Examples include Cervarix™ and Gardasil™, which are vaccines against human papilloma virus (HPV). Both of these vaccines target antigens derived from LI protein of a limited number of HPV strains. These vaccines do not provide protection against all strains of HPV. To expand the strain coverage of these vaccines, it is desirable to be able to admix additional viral antigens which are compatible with the existing vaccine formulations, which provide broader coverage and thereby create a new, expanded multivalent vaccine. It certain circumstances it may not be possible to simply blend in additional conventionally produced antigens to an existing vaccine because of undesirable interactions between the additional conventionally produced antigens and the existing vaccine (which may lead to precipitation, aggregation, etc.).

0008Therefore, what is needed are compositions and methods that could address the problems noted above that are associated with producing vaccines.

SUMMARY OF THE INVENTION

0010In one aspect, a dosage form comprising (1) a first population of synthetic nanocarriers that have one or more first antigens coupled to them, (2) one or more second antigens that are not coupled to the synthetic nanocarriers, and (3) a pharmaceutically acceptable excipient is provided.

0011In one embodiment, any of the dosage forms provided further comprises one or more adjuvants that are coupled to the synthetic nanocarriers of the first population of synthetic nanocarriers. In another embodiment, the one or more coupled adjuvants comprise any of the adjuvants as provided herein. In one embodiment, the one or more adjuvants comprise Pluronic® block co-polymers, specifically modified or prepared peptides, muramyl dipeptide, aminoalkyl glucosaminide 4-phosphates, RC529, bacterial toxoids, toxin fragments, agonists of Toll-Like Receptors 2, 3, 4, 5, 7, 8, 9 and/or combinations thereof; adenine derivatives; immuno stimulatory DNA; immunostimulatory RNA; imidazoquinoline amines, imidazopyridine amines, 6,7-fused

0012cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines; imiquimod; resiquimod; type I interferons; poly I:C; bacterial lipopolysacccharide (LPS); VSV-G; HMGB-1; flagellin or portions or derivatives thereof; or immunostimulatory DNA molecules comprising CpGs. In another embodiment, the one or more coupled adjuvants comprise an agonist of Toll-Like Receptor 2, 3, 4, 7, 8 or 9. In yet another embodiment, the one or more coupled adjuvants comprise an imidazoquinoline or oxoadenine. In still another embodiment, the imidazoquinoline comprises resiquimod or imiquimod.

0013In another embodiment, any of the dosage forms provided further comprises one or more adjuvants that are not coupled to the synthetic nanocarriers of the first population of synthetic nanocarriers. In one embodiment, the one or more not coupled adjuvants comprise stimulators or agonists of pattern recognition receptors, mineral salts, alum, alum combined with monphosphoryl lipid A of Enterobacteria (MPL), MPL® (AS04), AS15, saponins, QS-21,Quil-A, ISCOMs, ISCOMATRIX™, MF59™, Montanide® ISA 51, Montanide® ISA 720, AS02, liposomes and liposomal formulations, AS01, synthesized or specifically prepared microparticles and microcarriers, bacteria-derived outer membrane vesicles of N. gonorrheae or Chlamydia trachomatis, chitosan particles, depot-forming agents, Pluronic® block co-polymers, specifically modified or prepared peptides, muramyl dipeptide, aminoalkyl glucosaminide 4-phosphates, RC529, bacterial toxoids, toxin fragments, agonists of Toll-Like Receptors 2, 3, 4, 5, 7, 8, 9 and/or combinations thereof; adenine derivatives; immunostimulatory DNA; immunostimulatory RNA; imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines; imiquimod; resiquimod; agonist for DC surface molecule CD40; type I interferons; poly I:C; bacterial lipopolysacccharide (LPS); VSV-G; HMGB-1;

0014flagellin or portions or derivatives thereof; immunostimulatory DNA molecules comprising CpGs; proinflammatory stimuli released from necrotic cells; urate crystals; activated components of the complement cascade; activated components of immune complexes; complement receptor agonists; cytokines; or cytokine receptor agonists. In another embodiment, the one or more not coupled adjuvants comprise alum, AS01, AS02, AS04, AS15, MPL, QS-21, a saponin, or an immunostimulatory nucleic acid comprising CpG.

0015In yet another embodiment of any of the dosage forms provided, the one or more first antigens are identical to the one or more second antigens.

0016In a further embodiment, any of the dosage forms further comprises a second population of synthetic nanocarriers that have one or more third antigens coupled to them; wherein the first and third antigens are not identical.

0017In yet a further embodiment, the one or more first antigens of any of the dosage forms comprise a B cell antigen or a T cell antigen. In one embodiment, the T cell antigen is a universal T cell antigen or T-helper cell antigen. In another embodiment, the one or more first antigens comprise a B cell antigen or a T cell antigen and a a universal T cell antigen or T-helper cell antigen. In yet another embodiment, the T-helper cell antigen comprises a peptide obtained or derived from ovalbumin. In still another embodiment, the peptide obtained or derived from ovalbumin comprises the sequence as set forth in SEQ ID NO: 1. In an embodiment of any of the dosage forms, the a universal T cell antigen or T helper cell antigen is coupled by encapsulation. In another embodiment, the one or more second antigens of any of the dosage forms comprise a B cell antigen or a T cell antigen.

0018In one embodiment, any of the dosage forms provided comprises a vaccine that comprises the second antigen that is not coupled to the synthetic nanocarriers. In another embodiment, the vaccine comprises a hapten-carrier conjugate, a virus-like particle, a synthetic nanocarrier vaccine, a subunit protein vaccine, or an attenuated virus. In still another embodiment, the vaccine is any vaccine provided herein. In yet another

0019embodiment, the vaccine is against any infectious agent provided herein. In still another embodiment, the vaccine is against Anthrax; Diphtheria, Tetanus and/or Pertussis;

0020Haemophilus influenzae type B; Hepatitis B; Hepatitis A; Hepatitis C; Herpes zoster (shingles); Human Papillomavirus (HPV); Influenza; Japanese Encephalitis; Tick-borne Encephalitis; Measles, Mumps and/or Rubella; Meningococcal disease; Pneumococcal disease; Polio; Rabies; Rotavirus; Typhoid; Varicella; Vaccinia (Smallpox); or Yellow Fever. In a further embodiment, the vaccine comprises BIOTHRAX, DAPTACEL,

0021INFANRIX, TRIPEDIA, TRIHIBIT, KINRIX, PEDIARIX, PENTACEL, PEDVAXHIB, ACTHIB, HIBERIX, COMVAX, HAVRIX, VAQTA, ENGERIX-B, RECOMBIVAX HB, TWINRIX, ZOSTAVAX, GARDASIL, CERVARIX, FLUARIX, FLUVIRIN, FLUZONE, FLULAVAL, AFLURIA, AGRIFLU, FLUMIST, JE-VAX, IXIARO, M-M-R II,

0022PROQUAD, MENOMUNE, MENACTRA, MENVEO, PNEUMOVAX 23, PREVNAR, PCV13, IPOL, IMOVAX RABIES, RABAVERT, ROTATEQ, ROTARIX, DECAVAC, BOOSTRIX, ADACEL, TYPHIM VI, VIVOTIF BERNA, VARIVAX, ACAM2000 or YF- VAX.

0023In another embodiment, the one or more first antigens and/or one or more second antigens are obtained or derived from any of the infectious agents provided herein. In one embodiment, the infectious agent is a virus of the Adenoviridae, Picornaviridae,

0024Herpesviridae, Hepadnaviridae, Flaviviridae, Retroviridae, Orthomyxoviridae,

0025Paramyxoviridae, Papillomaviridae, Rhabdoviridae, Togaviridae or Paroviridae family. In still another embodiment, the one or more first antigens and/or one or more second antigens are obtained or derived from adenovirus, coxsackievirus, hepatitis A virus, poliovirus, Rhinovirus, Herpes simplex virus, Varicella-zoster virus, Epstein-barr virus, Human cytomegalovirus, Human herpesvirus, Hepatitis B virus, Hepatitis C virus, yellow fever virus, dengue virus, West Nile virus, HIV, Influenza virus, Measles virus, Mumps virus, Parainfluenza virus, Respiratory syncytial virus, Human metapneumovirus, Human papillomavirus, Rabies virus, Rubella virus, Human bocarivus or Parvovirus B19. In yet another embodiment, the one or more first antigens and/or one or more second antigens are obtained or derived from a bacteria of the Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia and Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema Vibrio or Yersinia genus. In a further embodiment, the one or more first antigens and/or one or more second antigens are obtained or derived from

0026Bordetella pertussis, Borrelia burgdorferi, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile,

0027Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitides, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Salmonella typhimurium, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophytics, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum, Vibrio cholerae or Yersinia pestis. In another embodiment, the one or more first antigens and/or one or more second antigens are obtained or derived from a fungus of the Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocystis or Stachybotrys genus. In still another embodiment, the one or more first antigens and/or one or more second antigens are obtained or derived from C. albicans, Aspergillus fumigatus, Aspergillus flavus, Cryptococcus neoformans, Cryptococcus laurentii, Cryptococcus albidus, Cryptococcus gattii, Histoplasma capsulatum, Pneumocystis jirovecii or

0028Stachybotrys chartarum.

0029In yet another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from any of the antigens provided herein. In one embodiment, the antigen comprises VI, VII, E1A, E3-19K, 52K, VP1, surface antigen, 3A protein, capsid protein, nucleocapsid, surface projection, transmembrane proteins, UL6, UL18, UL35, UL38, UL19, early antigen, capsid antigen, Pp65, gB, p52, latent nuclear antigen-1, NS3, envelope protein, envelope protein E2 domain, gpl20, p24, lipopeptides Gag (17-35), Gag (253-284), Nef (66-97), Nef (116-145), Pol (325-355), neuraminidase, nucleocapsid protein, matrix protein, phosphoprotein, fusion protein, hemagglutinin, hemagglutinin-neuraminidase, glycoprotein, E6, E7, envelope lipoprotein or non- structural protein (NS). In another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae (FIM 2/3), VlsE; DbpA, OspA, Hia, PrpA, MltA, L7/L12, D15, 0187, VirJ, Mdh, AfuA, L7/L12, out membrane protein, LPS, antigen type A, antigen type B, antigen type C, antigen type D, antigen type E, FliC, FliD, Cwp84, alpha-toxin, theta-toxin, fructose 1,6-biphosphate-aldolase (FBA), glyceraldehydes-3- phosphate dehydrogenase (GPD), pyruvate:ferredoxin oxidoreductase (PFOR), elongation factor-G (EF-G), hypothetical protein (HP), T toxin, Toxoid antigen, capsular

0030polysaccharide, Protein D, Mip, nucleoprotein (NP), RD1, PE35, PPE68, EsxA, EsxB, RD9, EsxV, Hsp70, lipopolysaccharide, surface antigen, Spl, Sp2, Sp3,

0031Glycerophosphodiester Phosphodiesterase, outer membrane protein, chaperone-usher protein, capsular protein (Fl) or V protein. In yet another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from surface antigen, capsular glycoprotein, Yps3P, Hsp60, Major surface protein, MsgCl, MsgC3, MsgC8, MsgC9 or SchS34.

0032In one embodiment of any of the dosage forms provided, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from one or more proteins of human papilloma virus. In another embodiment of any of the dosage forms provided, the one or more first antigens comprise or are obtained or derived from LI protein of human papilloma virus, and the one or more second antigens are obtained or derived from L2 protein of human papilloma virus. In yet another embodiment of any of the dosage forms provided, the one or more first antigens comprise or are obtained or derived from L2 protein of human papilloma virus, and the one or more second antigens are obtained or derived from LI protein of human papilloma virus. In still another embodiment of any of the dosage forms provided, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from one or more proteins of hepatitis B virus. In another embodiment of any of the dosage forms provided, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from hepatitis B surface antigen (HBsAg). In one embodiment, the HBsAg is from strain ayw produced in Saccharomyces cerevisiae. In another embodiment, when the one or more first antigens are obtained or derived from hepatitis B virus, the one or more second antigens comprise or are obtained or derived from one or more proteins of human papilloma virus. In a further embodiment, when the one or more second antigens are obtained or derived from hepatitis B virus, the one or more first antigens comprise or are obtained or derived from one or more proteins of human papilloma virus. In one embodiment, the one or more proteins of human papilloma virus is the LI and/or L2 protein of human papilloma virus. In another embodiment of any of the dosage forms provided, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from one or more proteins of influenza virus. In one embodiment, the influenza virus is influenza A virus, H5N1 avian influenza virus, or H1N1 influenza A virus. In another embodiment of any of the dosage forms provided, the one or more first antigens are obtained or derived from M2 protein of influenza A virus, and the one or more second antigens are obtained or derived from hemagglutinin of H5N1 avian influenza virus. In a further embodiment of any of the dosage forms provided, the one or more first antigens are obtained or derived from hemagglutinin of H5N1 avian influenza virus, and the one or more second antigens are obtained or derived from M2 protein of influenza A virus. In yet another embodiment of any of the dosage forms provided, the one or more first antigens are obtained or derived from M2 protein of influenza A virus, and the one or more second antigens are obtained or derived from beta-propiolactone-inactivated influenza A virus H1N1. In still another embodiment of any of the dosage forms provided, the one or more first antigens are obtained or derived from beta-propiolactone-inactivated influenza A virus H1N1, and the one or more second antigens are obtained or derived from M2 protein of influenza A virus.

0033In one embodiment of any of the dosage forms provided, the pharmaceutically acceptable excipient comprises a preservative, a buffer, saline, phosphate buffered saline, a colorant, or a stabilizer.

0034In another embodiment of any of the dosage forms provided, the first synthetic nanocarriers comprise lipid-based nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles, peptide or protein-based particles, lipid-polymer nanoparticles, spheroidal nanoparticles, cubic nanoparticles, pyramidal nanoparticles, oblong nanoparticles, cylindrical nanoparticles, or toroidal nanoparticles. In one embodiment, the first synthetic nanocarriers comprise one or more polymers. In another embodiment, the one or more polymers comprise a polyester. In yet another embodiment, the one or more polymers comprise or further comprise a polyester coupled to a hydrophilic polymer. In still another embodiment, the polyester comprises a poly(lactic acid), poly(glycolic acid), poly(lactic-co- glycolic acid), or polycaprolactone. In a further embodiment, the hydrophilic polymer comprises a polyether. In yet a further embodiment, the polyether comprises polyethylene glycol.

0035In another aspect, a method comprising administering any of the dosage forms provided to a subject is provided. In one embodiment, the subject has or is at risk of having an infection or infectious disease. In another embodiment, the subject has or is at risk of having cancer.

0036In one embodiment of any of the methods provided, the dosage form is administered by oral, subcutaneous, pulmonary, intranasal, intradermal or intramuscular administration. In yet another aspect, any of the dosage forms is provided for use in therapy or prophylaxis. In still another aspect, any of the dosage forms for use in any of the methods provided is provided. In yet another aspect, any of the dosage forms for use in a method of treating or preventing cancer is provided. In a further aspect, any of the dosage forms for use in a method of treating or preventing infection or infectious disease is provided. In one embodiment of any of the dosage forms, the method comprises administration of the dosage form by oral, subcutaneous, pulmonary, intranasal, intradermal or intramuscular

0037administration. In still another aspect, use of any of the dosage forms for the manufacture of a medicament for use in any of the methods is provided.

BRIEF DESCRIPTION OF FIGURES

0039Fig. 1 shows antibody titers in mice immunized with a combination of NC-M2e and free hemagglutinin from H5N1 avian influenza strain (Vietnam).

0040Fig. 2 shows antibody titers in mice immunized with a combination of NC-M2e and free hemagglutinin from H5N1 avian influenza strain (Vietnam) admixed with 80 μg of alum.

0041Fig. 3 shows antibody titers in mice immunized with a combination of NC-M2e and beta-propiolactone-inactivated influenza A virus HlNl (HlNl New Caledonia/20/99/ IVR 116) admixed with 80 μg of alum.

0042Fig. 4 shows antibody titers in mice immunized with a combination of NC-L2- peptide and HBsAg strain ayw produced in the yeast Saccharomyces cerevisiae admixed with 80 μg of alum. DETAILED DESCRIPTION OF THE INVENTION

0043Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified materials or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting of the use of alternative terminology to describe the present invention.

0044All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety for all purposes.

0045As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise. For example, reference to "a polymer" includes a mixture of two or more such molecules, reference to "a solvent" includes a mixture of two or more such solvents, reference to "an adhesive" includes mixtures of two or more such materials, and the like. INTRODUCTION

0046The inventors have unexpectedly and surprisingly discovered that the problems and limitations noted above can be overcome by practicing the invention disclosed herein. In particular, the inventors have unexpectedly discovered that it is possible to provide compositions, and related methods, that comprise a dosage form comprising a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.

0047In embodiments, the populations of synthetic nanocarriers may be combined with the one or more second antigens (which may be incorporated in a wide variety of ways) to form dosage forms according to the present invention. The one or more second antigens may be provided in solution form, suspension form, powder form, etc., and may be provided as a vaccine formulation. For instance, in an embodiment, the one or more second antigens may be provided in the form of a hapten-carrier protein or live attenuated virus vaccine formulation, and the population of synthetic nanocarriers admixed with the hapten-carrier protein or live attenuated virus vaccine formulations form a multivalent vaccine dosage form (or increase the valency of the hapten-carrier protein or live attenuated virus vaccine formulations). In another embodiment, the population of synthetic nanocarriers may be combined with proteins taken from an infectious organism to form a multivalent vaccine dosage form according to the invention. In another embodiment, the population of synthetic nanocarriers may be added to another population of synthetic nanocarriers that comprise the one or more second antigens to form a multivalent synthetic nanocarrier vaccine dosage form. In other embodiments, the population of synthetic nanocarriers may be combined with protein antigens in the form of virus like particles to form a multivalent vaccine dosage form according to the invention. In other embodiments, additional antigens beyond the one or more first and/or second antigens can be incorporated into the dosage form (through admixing, and other techniques disclosed herein or known conventionally).

0048In an embodiment, synthetic nanocarriers comprising one or more first antigens and optionally a a universal T cell antigen or T helper antigen and/or an adjuvant, can be added to one or more second antigens (e.g., an existing vaccine) to create a combination vaccine with expanded breadth of antigen coverage.

0049For example, the vaccines Gardasil® and Cervarix® for protection against HPV comprise protein antigen epitopes from the major structural protein LI protein derived from 4 and 2 sets of HPV strains, correspondingly. Vaccines with LI peptide antigens from as many as 9 different HPV strains are known. Such a vaccine with multiple peptide antigens would potentially protect the individual against most, but not all, HPV strains. If a population of synthetic nanocarriers comprising one or more peptide epitopes from another HPV structural protein, L2, is added to an existing LI protein-based vaccine, broader protection from an HPV challenge would be obtained with the potential of creating a "universal HPV vaccine." This population of water-dispersed L2 peptide synthetic nanocarriers can simply be admixed to the existing aqueous vaccine formulation much as one would add an excipient, or diluent, to the formulation. This simple method for expanding the breadth of coverage avoids having to engineer the L2 peptide into a recombinant protein antigen form as is conventionally done. This is illustrated in Examples 1 and 2 below, which together illustrate the formation of a combination HPV vaccine containing conventional Gardasil® augmented by synthetic nanocarriers comprising a peptide derived from L2 protein.

0050The inventive synthetic nanocarrier combination vaccine approach can be generalized to include other infectious disease prophylactic or therapeutic vaccines with less than 100% protection against the various strains of the infectious agent. It can also be used for prophylactic and/or therapeutic vaccines directed against non-infectious disease targets, such as cancer or small molecule agents. In embodiments, the inventive compositions provide for combinations of synthetic nanocarriers with existing "conventional" vaccines that can be formulated easily without the limitations of protein antigen solubility at higher concentrations. This can reduce multivalent vaccine volumes, and enhance ease of formulation.

0051Examples 3-6 and 8-11 show different embodiments of the present invention.

0052Examples 3 and 4 illustrate a combination vaccine of conventional hepatitis B vaccines augmented by synthetic nanocarriers which comprise surface adsorbed heparin as a first antigen. Examples 5 and 6 illustrate an oral combination vaccine of a conventional anti- rotaviral vaccine augmented by synthetic nanoparticles that comprise peptides derived from the L2 protein of HPV. Examples 8 and 9 illustrate a combination vaccine of free hemagglutinin from H5N1 avian influenza strain (Vietnam) augmented by synthetic nanocarriers that comprise M2e, OP-II T-helper peptide and R848 without or with admixed adjuvant, respectively. Example 10 illustrates a combination of inactivated influenza A virus H1N1 vaccine and augmented with synthetic nanocarriers that comprise M2e, OP-II T-helper peptide and R848 adjuvant with admixed alum. Example 11 illustrates a combination of recombinant hepatitis B surface antigen augmented with synthetic nanocarriers that comprise L2 peptide, OP-II T-helper peptide and R848 with admixed alum. The compositions exemplified in the Examples are also provided herein as are methods of their administration to a subject.

0053The invention will now be described in more detail below.

DEFINITIONS

0055"Adjuvant" means an agent that does not constitute a specific antigen, but boosts the strength and longevity of immune response to a co-administered antigen, preferably an antigen present in a dosage form together with the antigen, and more preferably a concomitantly administered antigen. Such adjuvants may include, but are not limited to stimulators of pattern recognition receptors, such as Toll-like receptors, RIG-1 and NOD- like receptors (NLR), mineral salts, such as alum, alum combined with monphosphoryl lipid (MPL) A of Enterobacteria, such as Escherihia coli, Salmonella minnesota, Salmonella typhimurium, or Shigella flexneri or specifically with MPL® (AS04), MPL A of above- mentioned bacteria separately, saponins, such as QS-21,Quil-A, ISCOMs,

0056ISCOMATRIX™, emulsions such as MF59™, Montanide® ISA 51 and ISA 720, AS02 (QS21+squalene+ MPL®), AS15, liposomes and liposomal formulations such as AS01, synthesized or specifically prepared microparticles and microcarriers such as bacteria- derived outer membrane vesicles (OMV) of N. gonorrheae, Chlamydia trachomatis and others, or chitosan particles, depot-forming agents, such as Pluronic® block co-polymers, specifically modified or prepared peptides, such as muramyl dipeptide, aminoalkyl glucosaminide 4-phosphates, such as RC529, or proteins, such as bacterial toxoids or toxin fragments.

0057In embodiments, adjuvants comprise agonists for pattern recognition receptors (PRR), including, but not limited to Toll-Like Receptors (TLRs), specifically TLRs 2, 3, 4, 5, 7, 8, 9 and/or combinations thereof. In other embodiments, adjuvants comprise agonists for Toll-Like Receptors 3, agonists for Toll-Like Receptors 7 and 8, or agonists for Toll- Like Receptor 9; preferably the recited adjuvants comprise imidazoquinolines; such as R848 (resiquimod); adenine derivatives, such as those disclosed in US patent 6,329,381

0058(Sumitomo Pharmaceutical Company), US Published Patent Application 2010/0075995 to Biggadike et al., or WO 2010/018132 to Campos et al.; immunostimulatory DNA; or immuno stimulatory RNA. In specific embodiments, synthetic nanocarriers incorporate as adjuvants compounds that are agonists for toll-like receptors (TLRs) 7 & 8 ("TLR 7/8 agonists"). Of utility are the TLR 7/8 agonist compounds disclosed in US Patent 6,696,076 to Tomai et al., including but not limited to imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines. Preferred adjuvants comprise imiquimod and resiquimod. In specific

0059embodiments, an adjuvant may be an agonist for the DC surface molecule CD40. In certain embodiments, to stimulate immunity rather than tolerance, a synthetic nanocarrier incorporates an adjuvant that promotes DC maturation (needed for priming of naive T cells) and the production of cytokines, such as type I interferons, which promote antibody immune responses. In embodiments, adjuvants also may comprise immunostimulatory RNA molecules, such as but not limited to dsRNA or poly Lpoly C12U (available as Ampligen®, both poly I:C and poly I:polyC12U being known as TLR3 stimulants), and/or those disclosed in F. Heil et al., "Species-Specific Recognition of Single-Stranded RNA via Toll- like Receptor 7 and 8" Science 303(5663), 1526-1529 (2004); J. Vollmer et al., "Immune modulation by chemically modified ribonucleosides and oligoribonucleotides" WO

00602008033432 A2; A. Forsbach et al., "Immunostimulatory oligoribonucleotides containing specific sequence motif(s) and targeting the Toll-like receptor 8 pathway" WO 2007062107 A2; E. Uhlmann et al., "Modified oligoribonucleotide analogs with enhanced immunostimulatory activity" U.S. Pat. Appl. Publ. US 2006241076; G. Lipford et al., "Immuno stimulatory viral RNA oligonucleotides and use for treating cancer and infections" WO 2005097993 A2; G. Lipford et al., "Immunostimulatory G,U-containing

0061oligoribonucleotides, compositions, and screening methods" WO 2003086280 A2. In some embodiments, an adjuvant may be a TLR-4 agonist, such as bacterial lipopolysacccharide (LPS), VSV-G, and/or HMGB-1. In some embodiments, adjuvants may comprise TLR-5 agonists, such as flagellin, or portions or derivatives thereof, including but not limited to those disclosed in US Patents 6,130,082, 6,585,980, and 7,192,725. In specific

0062embodiments, synthetic nanocarriers incorporate a ligand for Toll-like receptor (TLR)-9, such as immunostimulatory DNA molecules comprising CpGs, which induce type I interferon secretion, and stimulate T and B cell activation leading to increased antibody production and cytotoxic T cell responses (Krieg et al., CpG motifs in bacterial DNA trigger direct B cell activation. Nature. 1995. 374:546-549; Chu et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Thl) immunity. J. Exp. Med. 1997. 186:1623- 1631; Lipford et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 1997. 27:2340-2344; Roman et al. Immunostimulatory DNA sequences function as T helper- 1- promoting adjuvants. . Nat. Med. 1997. 3:849-854; Davis et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 1998. 160:870-876; Lipford et al., Bacterial DNA as immune cell activator. Trends Microbiol. 1998. 6:496-500; US Patent 6,207,646 to Krieg et al.; US Patent 7,223,398 to Tuck et al.; US Patent 7,250,403 to Van Nest et al.; or US Patent 7,566,703 to Krieg et al.

0063In some embodiments, adjuvants may be proinflammatory stimuli released from necrotic cells (e.g., urate crystals). In some embodiments, adjuvants may be activated components of the complement cascade (e.g., CD21, CD35, etc.). In some embodiments, adjuvants may be activated components of immune complexes. The adjuvants also include complement receptor agonists, such as a molecule that binds to CD21 or CD35. In some embodiments, the complement receptor agonist induces endogenous complement opsonization of the synthetic nanocarrier. In some embodiments, adjuvants are cytokines, which are small proteins or biological factors (in the range of 5 kD - 20 kD) that are released by cells and have specific effects on cell-cell interaction, communication and behavior of other cells. In some embodiments, the cytokine receptor agonist is a small molecule, antibody, fusion protein, or aptamer.

0064In embodiments, at least a portion of the dose of adjuvant may be coupled to synthetic nanocarriers, preferably, all of the dose of adjuvant is coupled to synthetic nanocarriers. In other embodiments, at least a portion of the dose of the adjuvant is not coupled to the synthetic nanocarriers. In embodiments, the dose of adjuvant comprises two or more types of adjuvants. For instance, and without limitation, adjuvants that act on different TLR receptors may be combined. As an example, in an embodiment a TLR 7/8 agonist may be combined with a TLR 9 agonist. In another embodiment, a TLR 7/8 agonist may be combined with a TLR 4 agonist. In yet another embodiment, a TLR 9 agonist may be combined with a TLR 3 agonist.

0065"Administering" or "administration" means providing a dosage form to a subject in a manner that is pharmacologically useful.

0066"Amount effective" is any amount of a composition that produces one or more desired immune responses. This amount can be for in vitro or in vivo purposes. For in vivo purposes, the amount can be one that a health practitioner would believe may have a clinical benefit for a subject in need of an antibody response specific to one or more antigens. In embodiments, therefore, an amount effective is one that a health practitioner would believe may generate an antibody response against the antigen(s) of the inventive compositions provided herein. Effective amounts can be monitored by routine methods. An amount that is effective to produce one or more desired immune responses can also be an amount of a composition provided herein that produces a desired therapeutic endpoint or a desired therapeutic result. Therefore, in other embodiments, the amount effective in one that a clinician would believe would provide a therapeutic benefit (including a prophylactic benefit) to a subject provided herein. Such subjects include those that have or are at risk of having cancer, an infection or infectious disease.

0067Amounts effective will depend, of course, on the particular subject being treated; the severity of a condition, disease or disorder; the individual patient parameters including age, physical condition, size and weight; the duration of the treatment; the nature of concurrent therapy (if any); the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a "maximum dose" be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons. The antigen(s) of any of the inventive compositions provided herein can in embodiments be in an amount effective.

0068"Antigen" means a B cell antigen or T cell antigen. In embodiments, antigens are coupled to the synthetic nanocarriers. In other embodiments, antigens are not coupled to the synthetic nanocarriers. In embodiments, dosage forms according to the invention comprise one or more antigens, for example, one or more first antigens, one or more second antigens, one or more third antigens, one or more fourth antigens, and one or more additional antigens. In embodiments, antigens are coadministered with the synthetic nanocarriers. In other embodiments antigens are not coadministered with the synthetic nanocarriers.

0069"Type(s) of antigens" means molecules that share the same, or substantially the same, antigenic characteristics.

0070"At least a portion of the dose" means at least some part of the dose, ranging up to including all of the dose.

0071An "at risk" subject is one in which a health practitioner believes has a chance of having a disease or condition provided herein including, but not limited to, an infection, infectious disease or cancer.

0072"B cell antigen" means any antigen that is or recognized by and triggers an immune response in a B cell (e.g., an antigen that is specifically recognized by a B cell receptor on a B cell). In some embodiments, an antigen that is a T cell antigen is also a B cell antigen. In other embodiments, the T cell antigen is not also a B cell antigen. B cell antigens include, but are not limited to, proteins, peptides, small molecules, and carbohydrates. In some embodiments, the B cell antigen comprises a non-protein antigen (i.e., not a protein or peptide antigen). In some embodiments, the B cell antigen comprises a carbohydrate associated with an infectious agent. In some embodiments, the B cell antigen comprises a glycoprotein or glycopeptide associated with an infectious agent. The infectious agent can be a bacterium, virus, fungus, protozoan, parasite or prion. In some embodiments, the B cell antigen comprises a poorly immunogenic antigen. In some embodiments, the B cell antigen comprises an abused substance or a portion thereof. In some embodiments, the B cell antigen comprises an addictive substance or a portion thereof. Addictive substances include, but are not limited to, nicotine, a narcotic, a cough suppressant, a tranquilizer, and a sedative. In some embodiments, the B cell antigen comprises a toxin, such as a toxin from a chemical weapon or natural sources, or a pollutant. The B cell antigen may also comprise a hazardous environmental agent. In some embodiments, the B cell antigen comprises a self antigen. In other embodiments, the B cell antigen comprises an alloantigen, an allergen, a contact sensitizer, a degenerative disease antigen, a hapten, an infectious disease antigen, a cancer antigen, an atopic disease antigen, an autoimmune disease antigen, an addictive substance, a xenoantigen, or a metabolic disease enzyme or enzymatic product thereof.

0073"Couple" or "Coupled" or "Couples" (and the like) means to chemically associate one entity (for example a moiety) with another. In some embodiments, the coupling is covalent, meaning that the coupling occurs in the context of the presence of a covalent bond between the two entities. In non-covalent embodiments, the non-covalent coupling is mediated by non-covalent interactions including but not limited to charge interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, hydrophobic interactions, TT stacking interactions, hydrogen bonding interactions, van der Waals interactions, magnetic interactions, electrostatic interactions, dipole-dipole interactions, and/or combinations thereof. In embodiments, encapsulation is a form of coupling. In embodiments, populations of synthetic nanocarriers have one or more antigens and/or adjuvants coupled to them, meaning that a plurality, preferably a majority, of the synthetic nanocarriers within the population have coupled to them one or more antigens and/or adjuvants that are similar to one another. In other embodiments, inventive dosage forms may comprise antigens and/or adjuvants that are not coupled to synthetic nanocarriers within a population of synthetic nanocarriers.

0074"Derived" means taken from a source and subjected to substantial modification. For instance, a peptide or nucleic acid with a sequence with only 50% identity to a natural peptide or nucleic acid, preferably a natural consensus peptide or nucleic acid, would be said to be derived from the natural peptide or nucleic acid. Substantial modification is modification that significantly affects the chemical or immunological properties of the material in question. Derived peptides and nucleic acids can also include those with a sequence with greater than 50% identity to a natural peptide or nucleic acid sequence if said derived peptides and nucleic acids have altered chemical or immunological properties as compared to the natural peptide or nucleic acid. These chemical or immunological properties comprise hydrophilicity, stability, affinity, and ability to couple with a carrier such as a synthetic nanocarrier. "Dosage form" means a pharmacologically and/or immunologically active material in a medium, carrier, vehicle, or device suitable for administration to a subject.

0075"Encapsulate" means to enclose within a synthetic nanocarrier, preferably enclose completely within a synthetic nanocarrier. Most or all of a substance that is encapsulated is not exposed to the local environment external to the synthetic nanocarrier. Encapsulation is distinct from absorption, which places most or all of a substance on a surface of a synthetic nanocarrier, and leaves the substance exposed to the local environment external to the synthetic nanocarrier.

0076"Identical" means that a substance shares one or more common chemical and/or immunological characteristics with another substance. For instance, one or more antigens are identical to one or more other antigens when both sets of antigens share one or more common chemical and/or immunological characteristics. Substances, such as antigens, are not identical when they fail to meet the criteria for being identical. Certain biologically active macromolecules may be described as having a percent identity with respect to one another, which is a measure of the matching of their sequences, as is conventionally known in the art. Such biologically active macromolecules are identical within the scope of this invention when they share greater than 20% identity, preferably greater than 30% identity, preferably greater than 40% identity, preferably greater than 50% identity, preferably greater than 60% identity, preferably greater than 70% identity, preferably greater than 80% identity, or preferably greater than 90% identity, with one another.

0077An "infection" or "infectious disease" is any condition or disease caused by a microorganism, pathogen or other agent, such as a bacterium, fungus, prion or virus.

0078"Isolated nucleic acid" means a nucleic acid that is separated from its native environment and present in sufficient quantity to permit its identification or use. An isolated nucleic acid may be one that is (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. Any of the nucleic acids provided herein may be isolated. In some embodiments, the antigens in the compositions provided herein are present in the form of an isolated nucleic acid, such as an isolated nucleic acid that encodes an antigenic peptide, polypeptide or protein.

0079"Isolated peptide, polypeptide or protein" means the polypeptide (or peptide or protein) is separated from its native environment and present in sufficient quantity to permit its identification or use. This means, for example, the polypeptide (or peptide or protein) may be (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated peptides, proteins or polypeptides may be, but need not be, substantially pure. Because an isolated peptide, polypeptide or protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the polypeptide (or peptide or protein) may comprise only a small percentage by weight of the preparation. The polypeptide (or peptide or protein) is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e., isolated from other proteins (or peptides or polypeptides). Any of the peptides, polypeptides or proteins provided herein may be isolated. In some embodiments, the antigens in the compositions provided herein are peptides, polypeptides or proteins.

0080"Maximum dimension of a synthetic nanocarrier" means the largest dimension of a nanocarrier measured along any axis of the synthetic nanocarrier. "Minimum dimension of a synthetic nanocarrier" means the smallest dimension of a synthetic nanocarrier measured along any axis of the synthetic nanocarrier. For example, for a spheroidal synthetic nanocarrier, the maximum and minimum dimension of a synthetic nanocarrier would be substantially identical, and would be the size of its diameter. Similarly, for a cuboidal synthetic nanocarrier, the minimum dimension of a synthetic nanocarrier would be the smallest of its height, width or length, while the maximum dimension of a synthetic nanocarrier would be the largest of its height, width or length. In an embodiment, a minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic

0081nanocarriers in the sample, is greater than 100 nm. In an embodiment, a maximum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is equal to or less than 5 μπι. Preferably, a minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is greater than 110 nm, more preferably greater than 120 nm, more preferably greater than 130 nm, and more preferably still greater than 150 nm. Aspects ratios of the maximum and minimum dimensions of inventive synthetic nanocarriers may vary depending on the embodiment. For instance, aspect ratios of the maximum to minimum dimensions of the synthetic nanocarriers may vary from 1:1 to 1,000,000:1, preferably from 1:1 to 100,000:1, more preferably from 1:1 to 1000:1, still preferably from 1:1 to 100:1, and yet more preferably from 1:1 to 10:1. Preferably, a maximum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample is equal to or less than 3 μπι, more preferably equal to or less than 2 μπι, more preferably equal to or less than 1 μπι, more preferably equal to or less than 800 nm, more preferably equal to or less than 600 nm, and more preferably still equal to or less than 500 nm. In preferred embodiments, a maximum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is equal to or greater than lOOnm, more preferably equal to or greater than 120 nm, more preferably equal to or greater than 130 nm, more preferably equal to or greater than 140 nm, and more preferably still equal to or greater than 150 nm. Measurement of synthetic nanocarrier sizes is obtained by suspending the synthetic nanocarriers in a liquid (usually aqueous) media and using dynamic light scattering (e.g. using a Brookhaven ZetaPALS instrument).

0082"Obtained" means taken from a source without substantial modification. Substantial modification is modification that significantly affects the chemical or immunological properties of the material in question. For example, as a non-limiting example, a peptide or nucleic acid with a sequence with greater than 90%, preferably greater than 95%, preferably greater than 97%, preferably greater than 98%, preferably greater than 99%, preferably 100%, identity to a natural peptide or nucleotide sequence, preferably a natural consensus peptide or nucleotide sequence, and chemical and/or immunological properties that are not significantly different from the natural peptide or nucleic acid, would be said to be obtained from the natural peptide or nucleotide sequence. These chemical or immunological properties comprise hydrophilicity, stability, affinity, and ability to couple with a carrier such as a synthetic nanocarrier.

0083"Pharmaceutically acceptable carrier(s) or excipient(s)" means materials that are contained within the dosage form, but do not contribute substantially to the primary pharmacological activity of the dosage form. In embodiments, the materials are

0084pharmacologically inactive. In embodiments, pharmaceutically acceptable excipients comprise preservatives, buffers, saline, or phosphate buffered saline, colorants, or stabilizers. Pharmaceutically acceptable excipients comprise a variety of materials known in the art, including but not limited to saccharides (such as glucose, lactose, and the like), preservatives such as antimicrobial agents, reconstitution aids, colorants, saline (such as phosphate buffered saline), and buffers.

0085"Population" means a defined group of synthetic nanocarriers that share one or more common physical or chemical characteristics. Common physical or chemical characteristics may comprise having a common coupled antigen(s), common coupled adjuvant(s), common materials making up the bulk nanocarrier, a common shape, a common particle size, and the like. Multiple populations of synthetic nanocarriers may be identified, for example a first population, a second population, a third population, a fourth population, and the like.

0086"Subject" means animals, including warm blooded mammals such as humans and primates; avians; domestic household or farm animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs; fish; reptiles; zoo and wild animals; and the like.

0087"Synthetic nanocarrier(s)" means a discrete object that is not found in nature, and that possesses at least one dimension that is less than or equal to 5 microns in size.

0088Albumin nanoparticles are generally included as synthetic nanocarriers, however in certain embodiments the synthetic nanocarriers do not comprise albumin nanoparticles. In embodiments, inventive synthetic nanocarriers do not comprise chitosan.

0089A synthetic nanocarrier can be, but is not limited to, one or a plurality of lipid-based nanoparticles (e.g. liposomes) (also referred to herein as lipid nanoparticles, i.e., nanoparticles where the majority of the material that makes up their structure are lipids), polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles (i.e., particles that are primarily made up of viral structural proteins but that are not infectious or have low infectivity), peptide or protein- based particles (also referred to herein as protein particles, i.e., particles where the majority of the material that makes up their structure are peptides or proteins) (such as albumin nanoparticles) and/or nanoparticles that are developed using a combination of nanomaterials such as lipid-polymer nanoparticles. Synthetic nanocarriers may be a variety of different shapes, including but not limited to spheroidal, cuboidal, pyramidal, oblong, cylindrical, toroidal, and the like. Synthetic nanocarriers according to the invention comprise one or more surfaces, including but not limited to internal surfaces (surfaces generally facing an interior portion of the synthetic nanocarrier) and external surfaces (surfaces generally facing an external environment of the synthetic nanocarrier). Exemplary synthetic nanocarriers that can be adapted for use in the practice of the present invention comprise: (1) the biodegradable nanoparticles disclosed in US Patent 5,543,158 to Gref et al., (2) the polymeric nanoparticles of Published US Patent Application 20060002852 to Saltzman et al., (3) the lithographically constructed nanoparticles of Published US Patent Application 20090028910 to DeSimone et al., (4) the disclosure of WO 2009/051837 to von Andrian et al., (5) the nanoparticles disclosed in Published US Patent Application 2008/0145441 to Penades et al., (6) the protein nanoparticles disclosed in Published US Patent Application 20090226525 to de los Rios et al., (7) the virus-like particles disclosed in published US Patent Application 20060222652 to Sebbel et al., (8) the nucleic acid coupled virus-like particles disclosed in published US Patent Application 20060251677 to Bachmann et al., (9) the virus-like particles disclosed in WO2010047839A1 or WO2009106999A2, or (10) the nanoprecipitated nanoparticles disclosed in P. Paolicelli et al., "Surface-modified PLGA- based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles" Nanomedicine. 5(6):843-853 (2010). In embodiments, synthetic nanocarriers may possess an aspect ratio greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7, or greater than 1:10.

0090Synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise a surface with hydroxyl groups that activate complement or alternatively comprise a surface that consists essentially of moieties that are not hydroxyl groups that activate complement. In a preferred embodiment, synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise a surface that substantially activates complement or alternatively comprise a surface that consists essentially of moieties that do not substantially activate complement. In a more preferred embodiment, synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise a surface that activates complement or alternatively comprise a surface that consists essentially of moieties that do not activate complement. In embodiments, synthetic nanocarriers exclude virus-like particles. In embodiments, when synthetic nanocarriers comprise virus-like particles, the virus-like particles comprise non-natural adjuvant (meaning that the VLPs comprise an adjuvant other than naturally occurring RNA generated during the production of the VLPs). In

0091embodiments, synthetic nanocarriers may possess an aspect ratio greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7, or greater than 1:10.

0092"T cell antigen" means any antigen that is recognized by and triggers an immune response in a T cell (e.g., an antigen that is specifically recognized by a T cell receptor on a T cell or an NKT cell via presentation of the antigen or portion thereof bound to a Class I or Class II major histocompatability complex molecule (MHC), or bound to a CD1 complex. In some embodiments, an antigen that is a T cell antigen is also a B cell antigen. In other embodiments, the T cell antigen is not also a B cell antigen. T cell antigens generally are proteins or peptides. T cell antigens may be an antigen that stimulates a CD8+ T cell response, a CD4+ T cell response, or both. The nanocarriers, therefore, in some

0093embodiments can effectively stimulate both types of responses.

0094In some embodiments the T cell antigen is a 'universal' T cell antigen, or T cell memory antigen, (i.e., one to which a subject has a pre-existing memory and that can be used to boost T cell help to an unrelated antigen, for example an unrelated B cell antigen). Universal T cell antigens include tetanus toxoid, as well as one or more peptides derived from tetanus toxoid, Epstein-Barr virus, or influenza virus. Universal T cell antigens also include a components of influenza virus, such as hemagglutinin, neuraminidase, or nuclear protein, or one or more peptides derived therefrom. In some embodiments, the universal T cell antigen is not one that is presented in a complex with a MHC molecule. In some embodiments, the universal T cell antigen is not complexed with a MHC molecule for presentation to a T helper cell. Accordingly, in some embodiments, the universal T cell antigen is not a T helper cell antigen. However, in other embodiments, the universal T cell antigen is a T helper cell antigen.

0095In embodiments, a T-helper cell antigen may comprise one or more peptides obtained or derived from tetanus toxoid, Epstein-Barr virus, influenza virus, respiratory syncytial virus, measles virus, mumps virus, rubella virus, cytomegalovirus, adenovirus, diphtheria toxoid, or a PADRE peptide (known from the work of Sette et al. US Patent 7,202,351). In other embodiments, a T-helper cell antigen may comprise ovalbumin or a peptide obtained or derived therefrom. Preferably, the ovalbumin comprises the amino acid sequence as set forth in Accession No. AAB59956, NP_990483.1, AAA48998, or

0096CAA2371. In other embodiments, the peptide obtained or derived from ovalbumin comprises the following amino acid sequence: H-Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His- Ala-Glu-Ile-Asn-Glu-Ala-Gly-Arg-OH (SEQ ID NO: 1). In other embodiments, a T-helper cell antigen may comprise one or more lipids, or glycolipids, including but not limited to: a- galactosylceramide (a -GalCer), a -linked glycosphingolipids (from Sphingomonas spp.), galactosyl diacylglycerols (from Borrelia burgdorferi), lypophosphoglycan (from

0097Leishmania donovani), and phosphatidylinositol tetramannoside (PIM4) (from

0098Mycobacterium leprae). For additional lipids and/or glycolipids useful as T-helper cell antigen, see V. Cerundolo et al., "Harnessing invariant NKT cells in vaccination strategies." Nature Rev Immun, 9:28-38 (2009).

0099In embodiments, CD4+ T-cell antigens may be derivatives of a CD4+ T-cell antigen that is obtained from a source, such as a natural source. In such embodiments, CD4+ T-cell antigen sequences, such as those peptides that bind to MHC II, may have at least 70%, 80%, 90%, or 95% identity to the antigen obtained from the source. In embodiments, the T cell antigen, preferably a universal T cell antigen or T-helper cell antigen, may be coupled to, or uncoupled from, a synthetic nanocarrier. In some embodiments, the universal T cell antigen or T-helper cell antigen is encapsulated in the synthetic nanocarriers of the inventive compositions.

0100"Vaccine" means a composition of matter that improves the immune response to a particular pathogen or disease. A vaccine typically contains factors that stimulate a subject's immune system to recognize a specific antigen as foreign and eliminate it from the subject's body. A vaccine also establishes an immunologic 'memory' so the antigen will be quickly recognized and responded to if a person is re-challenged. Vaccines can be prophylactic (for example to prevent future infection by any pathogen), or therapeutic (for example a vaccine against a tumor specific antigen for the treatment of cancer). In embodiments, a vaccine may comprise dosage forms according to the invention. In other embodiments, the inventive dosage form may comprise a vaccine comprising the second antigen that is not coupled to the synthetic nanocarriers. Vaccines according to the invention may comprise a hapten-carrier conjugate, a virus-like particle, a synthetic nanocarrier vaccine, a subunit protein vaccine, or an attenuated virus. In some embodiments, the vaccine comprises any of the vaccines, including the commercially available vaccines, described herein. INVENTIVE COMPOSITIONS

0101A wide variety of synthetic nanocarriers can be used according to the invention. In some embodiments, synthetic nanocarriers are spheres or spheroids. In some embodiments, synthetic nanocarriers are flat or plate- shaped. In some embodiments, synthetic nanocarriers are cubes or cuboidal. In some embodiments, synthetic nanocarriers are ovals or ellipses. In some embodiments, synthetic nanocarriers are cylinders, cones, or pyramids.

0102In some embodiments, it is desirable to use a population of synthetic nanocarriers that is relatively uniform in terms of size, shape, and/or composition so that each synthetic nanocarrier has similar properties. For example, at least 80%, at least 90%, or at least 95% of the synthetic nanocarriers, based on the total number of synthetic nanocarriers, may have a minimum dimension or maximum dimension that falls within 5%, 10%, or 20% of the average diameter or average dimension of the synthetic nanocarriers. In some

0103embodiments, a population of synthetic nanocarriers may be heterogeneous with respect to size, shape, and/or composition.

0104Synthetic nanocarriers can be solid or hollow and can comprise one or more layers. In some embodiments, each layer has a unique composition and unique properties relative to the other layer(s). To give but one example, synthetic nanocarriers may have a core/shell structure, wherein the core is one layer (e.g. a polymeric core) and the shell is a second layer (e.g. a lipid bilayer or monolayer). Synthetic nanocarriers may comprise a plurality of different layers.

0105In some embodiments, synthetic nanocarriers may optionally comprise one or more lipids. In some embodiments, a synthetic nanocarrier may comprise a liposome. In some embodiments, a synthetic nanocarrier may comprise a lipid bilayer. In some embodiments, a synthetic nanocarrier may comprise a lipid monolayer. In some embodiments, a synthetic nanocarrier may comprise a micelle. In some embodiments, a synthetic nanocarrier may comprise a core comprising a polymeric matrix surrounded by a lipid layer (e.g., lipid bilayer, lipid monolayer, etc.). In some embodiments, a synthetic nanocarrier may comprise a non-polymeric core (e.g., metal particle, quantum dot, ceramic particle, bone particle, viral particle, proteins, nucleic acids, carbohydrates, etc.) surrounded by a lipid layer (e.g., lipid bilayer, lipid monolayer, etc.).

0106In some embodiments, synthetic nanocarriers can comprise one or more polymers.

0107In some embodiments, such a polymer can be surrounded by a coating layer (e.g., liposome, lipid monolayer, micelle, etc.). In some embodiments, various elements of the synthetic nanocarriers can be coupled with the polymer.

0108In some embodiments, an immunofeature surface, targeting moiety, antigen, adjuvant and/or oligonucleotide can be covalently associated with a polymeric matrix. In some embodiments, covalent association is mediated by a linker. In some embodiments, an immunofeature surface, targeting moiety, antigen, adjuvant and/or oligonucleotide can be noncovalently associated with a polymeric matrix. For example, in some embodiments, an immunofeature surface, targeting moiety, antigen, adjuvant and/or oligonucleotide can be adsorbed upon, encapsulated within, surrounded by, and/or dispersed throughout a polymeric matrix. Alternatively or additionally, an immunofeature surface, targeting moiety, antigen, adjuvant and/or nucleotide can be associated with a polymeric matrix by hydrophobic interactions, charge interactions, van der Waals forces, etc.

0109A wide variety of polymers and methods for forming polymeric matrices therefrom are known conventionally. In general, a polymeric matrix comprises one or more polymers.

0110Polymers may be natural or unnatural (synthetic) polymers. Polymers may be

0111homopolymers or copolymers comprising two or more monomers. In terms of sequence, copolymers may be random, block, or comprise a combination of random and block sequences. Typically, polymers in accordance with the present invention are organic polymers.

0112Examples of polymers suitable for use in the present invention include, but are not limited to polyethylenes, polycarbonates (e.g. poly(l,3-dioxan-2one)), polyanhydrides (e.g. poly(sebacic anhydride)), polypropylfumerates, polyamides (e.g. polycaprolactam), polyacetals, polyethers, polyesters (e.g., polylactide, polyglycolide, polylactide-co- glycolide, polycaprolactone, polyhydroxyacid (e.g. poly(P-hydroxyalkanoate)),

0113poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes,

0114polyphosphazenes, polyacrylates, polymethacrylates, polyureas, polystyrenes, polyamines, polylysine, polylysine-PEG copolymers, and poly(ethyleneimine), poly(ethylene imine)- PEG copolymers. In some embodiments, polymers in accordance with the present invention include polymers which have been approved for use in humans by the U.S. Food and Drug

0115Administration (FDA) under 21 C.F.R. § 177.2600, including but not limited to polyesters (e.g., polylactic acid, poly(lactic-co-glycolic acid); polycaprolactone (e.g., poly(l,3-dioxan- 2one)); polyvalerolactone; polyanhydrides (e.g., poly(sebacic anhydride)); polyethers (e.g., polyethylene glycol); polyurethanes; polymethacrylates; polyacrylates; and

0116polycyanoacrylates.

0117In some embodiments, polymers can be hydrophilic. For example, polymers may comprise anionic groups (e.g., phosphate group, sulphate group, carboxylate group);

0118cationic groups (e.g., quaternary amine group); or polar groups (e.g., hydroxyl group, thiol group, amine group). In some embodiments, a synthetic nanocarrier comprising a hydrophilic polymeric matrix generates a hydrophilic environment within the synthetic nanocarrier. In some embodiments, polymers can be hydrophobic. In some embodiments, a synthetic nanocarrier comprising a hydrophobic polymeric matrix generates a hydrophobic environment within the synthetic nanocarrier. Selection of the hydrophilicity or

0119hydrophobicity of the polymer may have an impact on the nature of materials that are incorporated (e.g. coupled) within the synthetic nanocarrier.

0120In some embodiments, polymers may be modified with one or more moieties and/or functional groups. A variety of moieties or functional groups can be used in accordance with the present invention. In some embodiments, polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from polysaccharides (Papisov, 2001, ACS Symposium Series, 786:301). Certain embodiments may be made using the general teachings of US Patent No. 5543158 to Gref et al., or WO publication WO2009/051837 by Von Andrian et al.

0121In some embodiments, polymers may be modified with a lipid or fatty acid group. In some embodiments, a fatty acid group may be one or more of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, or lignoceric acid. In some embodiments, a fatty acid group may be one or more of palmitoleic, oleic, vaccenic, linoleic, alpha-linoleic, gamma-linoleic, arachidonic, gadoleic, arachidonic,

0122eicosapentaenoic, docosahexaenoic, or erucic acid.

0123In some embodiments, polymers may be polyesters, including copolymers comprising lactic acid and glycolic acid units, such as poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide), collectively referred to herein as "PLGA"; and homopolymers comprising glycolic acid units, referred to herein as "PGA," and lactic acid units, such as poly-L-lactic acid, poly-D-lactic acid, poly-D,L-lactic acid, poly-L-lactide, poly-D-lactide, and poly-D,L-lactide, collectively referred to herein as "PLA." In some embodiments, exemplary polyesters include, for example, polyhydroxyacids; PEG copolymers and copolymers of lactide and glycolide (e.g., PLA-PEG copolymers, PGA-PEG copolymers, PLGA-PEG copolymers, and derivatives thereof. In some embodiments, polyesters include, for example, poly(caprolactone), poly(caprolactone)-PEG copolymers, poly(L-lactide-co-L- lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[a-(4-aminobutyl)-L- glycolic acid], and derivatives thereof.

0124In some embodiments, a polymer may be PLGA. PLGA is a biocompatible and biodegradable co-polymer of lactic acid and glycolic acid, and various forms of PLGA are characterized by the ratio of lactic acid:glycolic acid. Lactic acid can be L-lactic acid, D- lactic acid, or D,L-lactic acid. The degradation rate of PLGA can be adjusted by altering the lactic acid: glycolic acid ratio. In some embodiments, PLGA to be used in accordance with the present invention is characterized by a lactic acid:glycolic acid ratio of approximately 85:15, approximately 75:25, approximately 60:40, approximately 50:50, approximately 40:60, approximately 25:75, or approximately 15:85.

0125In some embodiments, polymers may be one or more acrylic polymers. In certain embodiments, acrylic polymers include, for example, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly( acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, glycidyl methacrylate copolymers, polycyanoacrylates, and combinations comprising one or more of the foregoing polymers. The acrylic polymer may comprise fully-polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.

0126In some embodiments, polymers can be cationic polymers. In general, cationic polymers are able to condense and/or protect negatively charged strands of nucleic acids (e.g. DNA, or derivatives thereof). Amine-containing polymers such as poly(lysine) (Zauner et al., 1998, Adv. Drug Del. Rev., 30:97; and Kabanov et al., 1995, Bioconjugate Chem., 6:7), polyethylene imine) (PEI; Boussif et al., 1995, Proc. Natl. Acad. Sci., USA, 1995, 92:7297), and poly(amidoamine) dendrimers (Kukowska-Latallo et al., 1996, Proc. Natl. Acad. Sci., USA, 93:4897; Tang et al., 1996, Bioconjugate Chem., 7:703; and Haensler et al., 1993, Bioconjugate Chem., 4:372) are positively-charged at physiological pH, form ion pairs with nucleic acids, and mediate transfection in a variety of cell lines. In embodiments, the inventive synthetic nanocarriers may not comprise (or may exclude) cationic polymers.

0127In some embodiments, polymers can be degradable polyesters bearing cationic side chains (Putnam et al., 1999, Macromolecules, 32:3658; Barrera et al., 1993, J. Am. Chem. Soc, 115:11010; Kwon et al., 1989, Macromolecules, 22:3250; Lim et al., 1999, J. Am. Chem. Soc, 121:5633; and Zhou et al., 1990, Macromolecules, 23:3399). Examples of these polyesters include poly(L-lactide-co-L-lysine) (Barrera et al., 1993, J. Am. Chem. Soc, 115:11010), poly(serine ester) (Zhou et al., 1990, Macromolecules, 23:3399), poly(4- hydroxy-L-proline ester) (Putnam et al., 1999, Macromolecules, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc, 121:5633), and poly(4-hydroxy-L-proline ester) (Putnam et al.,

01281999, Macromolecules, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc, 121:5633).

0129The properties of these and other polymers and methods for preparing them are well known in the art (see, for example, U.S. Patents 6,123,727; 5,804,178; 5,770,417;

01305,736,372; 5,716,404; 6,095,148; 5,837,752; 5,902,599; 5,696,175; 5,514,378; 5,512,600; 5,399,665; 5,019,379; 5,010,167; 4,806,621; 4,638,045; and 4,946,929; Wang et al., 2001, J. Am. Chem. Soc, 123:9480; Lim et al., 2001, J. Am. Chem. Soc, 123:2460; Langer,

01312000, Acc. Chem. Res., 33:94; Langer, 1999, J. Control. Release, 62:7; and Uhrich et al., 1999, Chem. Rev., 99:3181). More generally, a variety of methods for synthesizing certain suitable polymers are described in Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts, Ed. by Goethals, Pergamon Press, 1980; Principles of Polymerization by Odian, John Wiley & Sons, Fourth Edition, 2004; Contemporary

0132Polymer Chemistry by Allcock et al., Prentice-Hall, 1981; Deming et al., 1997, Nature, 390:386; and in U.S. Patents 6,506,577, 6,632,922, 6,686,446, and 6,818,732.

0133In some embodiments, polymers can be linear or branched polymers. In some embodiments, polymers can be dendrimers. In some embodiments, polymers can be substantially cross-linked to one another. In some embodiments, polymers can be substantially free of cross-links. In some embodiments, polymers can be used in accordance with the present invention without undergoing a cross-linking step. It is further to be understood that inventive synthetic nanocarriers may comprise block copolymers, graft copolymers, blends, mixtures, and/or adducts of any of the foregoing and other polymers. Those skilled in the art will recognize that the polymers listed herein represent an exemplary, not comprehensive, list of polymers that can be of use in accordance with the present invention.

0134In some embodiments, the synthetic nanocarriers comprise one or more polymers. The polymeric synthetic nanocarriers, therefore, can also include those described in WO publication WO2009/051837 by Von Andrian et al., including, but not limited to those, with one or more hydrophilic components. Preferably, the one or more polymers comprise a polyester, such as a poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), or polycaprolactone. More preferably, the one or more polymers comprise or further comprise a polyester coupled to a hydrophilic polymer, such as a polyether. In embodiments, the polyether comprises polyethylene glycol. Still more preferably, the one or more polymers comprise a polyester and a polyester coupled to a hydrophilic polymer, such as a polyether. In other embodiments, the one or more polymers are coupled to one or more antigens and/or one or more adjuvants. In embodiments, at least some of the polymers are coupled to the antigen(s) and/or at least some of the polymers are coupled to the adjuvant(s). Preferably, when there are more than one type of polymer, one of the types of polymer is coupled to the antigen(s). In embodiments, one of the other types of polymer is coupled to the adjuvant(s). For example, in embodiments, when the nanocarriers comprise a polyester and a polyester coupled to a hydrophilic polymer, such as a polyether, the polyester is coupled to the adjuvant, while the polyester coupled to the hydrophilic polymer, such as a polyether, is coupled to the antigen(s). In embodiments, where the nanocarriers comprise a T helper cell antigen, the T helper cell antigen can be encapsulated in the nanocarrier.

0135In some embodiments, synthetic nanocarriers do not comprise a polymeric component. In some embodiments, synthetic nanocarriers may comprise metal particles, quantum dots, ceramic particles, etc. In some embodiments, a non-polymeric synthetic nanocarrier is an aggregate of non-polymeric components, such as an aggregate of metal atoms (e.g., gold atoms).

0136In some embodiments, synthetic nanocarriers may optionally comprise one or more amphiphilic entities. In some embodiments, an amphiphilic entity can promote the production of synthetic nanocarriers with increased stability, improved uniformity, or increased viscosity. In some embodiments, amphiphilic entities can be associated with the interior surface of a lipid membrane (e.g., lipid bilayer, lipid monolayer, etc.). Many amphiphilic entities known in the art are suitable for use in making synthetic nanocarriers in accordance with the present invention. Such amphiphilic entities include, but are not limited to, phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol;

0137diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acids; fatty acid monoglycerides; fatty acid diglycerides; fatty acid amides; sorbitan trioleate (Span®85) glycocholate; sorbitan monolaurate (Span®20); polysorbate 20 (Tween®20); polysorbate 60 (Tween®60);

0138polysorbate 65 (Tween®65); polysorbate 80 (Tween®80); polysorbate 85 (Tween®85); polyoxyethylene monostearate; surfactin; a poloxomer; a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine;

0139phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebrosides; dicetylphosphate; dipalmitoylphosphatidylglycerol;

0140stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate;

0141hexadecyl sterate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000- phosphatidylethanolamine; poly(ethylene glycol)400-monostearate; phospholipids;

0142synthetic and/or natural detergents having high surfactant properties; deoxycholates;

0143cyclodextrins; chaotropic salts; ion pairing agents; and combinations thereof. An amphiphilic entity component may be a mixture of different amphiphilic entities. Those skilled in the art will recognize that this is an exemplary, not comprehensive, list of substances with surfactant activity. Any amphiphilic entity may be used in the production of synthetic nanocarriers to be used in accordance with the present invention.

0144In some embodiments, synthetic nanocarriers may optionally comprise one or more carbohydrates. Carbohydrates may be natural or synthetic. A carbohydrate may be a derivatized natural carbohydrate. In certain embodiments, a carbohydrate comprises monosaccharide or disaccharide, including but not limited to glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellbiose, mannose, xylose, arabinose, glucoronic acid, galactoronic acid, mannuronic acid, glucosamine, galatosamine, and neuramic acid. In certain embodiments, a carbohydrate is a polysaccharide, including but not limited to pullulan, cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), hydroxycellulose (HC), methylcellulose (MC), dextran, cyclodextran, glycogen, starch, hydroxyethylstarch, carageenan, glycon, amylose, chitosan, Ν,Ο- carboxylmethylchitosan, algin and alginic acid, starch, chitin, inulin, konjac, glucommannan, pustulan, heparin, hyaluronic acid, curdlan, and xanthan. In embodiments, the inventive synthetic nanocarriers do not comprise (or specifically exclude) carbohydrates, such as a polysaccharide. In certain embodiments, the carbohydrate may comprise a carbohydrate derivative such as a sugar alcohol, including but not limited to mannitol, sorbitol, xylitol, erythritol, maltitol, and lactitol.

0145Compositions according to the invention comprise inventive synthetic nanocarriers in combination with pharmaceutically acceptable excipients, such as preservatives, buffers, saline, or phosphate buffered saline. The compositions may be made using conventional pharmaceutical manufacturing and compounding techniques to arrive at useful dosage forms. Typical inventive compositions may comprise inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate, or citrate) and pH adjustment agents (e.g., hydrochloric acid, sodium or potassium hydroxide, salts of citrate or acetate, amino acids and their salts) antioxidants (e.g., ascorbic acid, alpha- tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene9-10 nonyl phenol, sodium

0146desoxycholate), solution and/or cryo/lyo stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic adjustment agents (e.g., salts or sugars), antibacterial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g., polydimethylsilozone), preservatives (e.g., thimerosal, 2-phenoxyethanol, EDTA), polymeric stabilizers and viscosity-adjustment agents (e.g., polyvinylpyrrolidone, poloxamer 488,

0147carboxymethylcellulose) and co-solvents (e.g., glycerol, polyethylene glycol, ethanol). In an embodiment, inventive synthetic nanocarriers are suspended in sterile saline solution for injection together with a preservative.

0148In embodiments, when preparing synthetic nanocarriers as carriers for antigens or adjuvants for use in vaccines, methods for coupling the antigens or adjuvants to the synthetic nanocarriers may be useful. If the antigens or adjuvant is a small molecule it may be of advantage to attach the antigens or adjuvant to a polymer prior to the assembly of the synthetic nanocarriers. In embodiments, it may also be an advantage to prepare the synthetic nanocarriers with surface groups that are used to couple the antigens or adjuvant to the synthetic nanocarrier through the use of these surface groups rather than attaching the antigens or adjuvant to a polymer and then using this polymer conjugate in the construction of synthetic nanocarriers.

0149In certain embodiments, the coupling can be a covalent linker. In embodiments, peptides according to the invention can be covalently coupled to the external surface via a 1,2,3-triazole linker formed by the 1,3-dipolar cycloaddition reaction of azido groups on the surface of the nanocarrier with antigen or adjuvant containing an alkyne group or by the 1,3-dipolar cycloaddition reaction of alkynes on the surface of the nanocarrier with antigens or adjuvants containing an azido group. Such cycloaddition reactions are preferably performed in the presence of a Cu(I) catalyst along with a suitable Cu(I)-ligand and a reducing agent to reduce Cu(II) compound to catalytic active Cu(I) compound. This Cu(I)- catalyzed azide-alkyne cycloaddition (CuAAC) can also be referred as the click reaction.

0150Additionally, the covalent coupling may comprise a covalent linker that comprises an amide linker, a disulfide linker, a thioether linker, a hydrazone linker, a hydrazide linker, an imine or oxime linker, an urea or thiourea linker, an amidine linker, an amine linker, and a sulfonamide linker.

0151An amide linker is formed via an amide bond between an amine on one component such as the antigen or adjuvant with the carboxylic acid group of a second component such as the nanocarrier. The amide bond in the linker can be made using any of the conventional amide bond forming reactions with suitably protected amino acids or antigens or adjuvants and activated carboxylic acid such N-hydroxysuccinimide-activated ester.

0152A disulfide linker is made via the formation of a disulfide (S-S) bond between two sulfur atoms of the form, for instance, of R1-S-S-R2. A disulfide bond can be formed by thiol exchange of an antigen or adjuvant containing thiol/mercaptan group(-SH) with another activated thiol group on a polymer or nanocarrier or a nanocarrier containing thiol/mercaptan groups with a antigen or adjuvant containing activated thiol group.

0153A triazole linker, specifically a 1,2,3-triazole of the form <img file="EP2575773A2_D0001.tif" /> , wherein Rl and

0154R2 may be any chemical entities, is made by the 1,3-dipolar cycloaddition reaction of an azide attached to a first component such as the nanocarrier with a terminal alkyne attached to a second component such as the peptide. The 1,3-dipolar cycloaddition reaction is performed with or without a catalyst, preferably with Cu(I)-catalyst, which links the two components through a 1,2,3-triazole function. This chemistry is described in detail by Sharpless et al., Angew. Chem. Int. Ed. 41(14), 2596, (2002) and Meldal, et al, Chem. Rev., 2008, 108(8), 2952-3015 and is often referred to as a "click" reaction or CuAAC. In embodiments, a polymer containing an azide or alkyne group, terminal to the polymer chain is prepared. This polymer is then used to prepare a synthetic nanocarrier in such a manner that a plurality of the alkyne or azide groups are positioned on the surface of that nanocarrier. Alternatively, the synthetic nanocarrier can be prepared by another route, and subsequently functionalized with alkyne or azide groups. The antigen or adjuvantis prepared with the presence of either an alkyne (if the polymer contains an azide) or an azide (if the polymer contains an alkyne) group. The antigen or adjuvant is then allowed to react with the nanocarrier via the 1,3-dipolar cycloaddition reaction with or without a catalyst which covalently couples the antigen or adjuvant to the particle through the 1,4- disubstituted 1,2,3-triazole linker.

0155A thioether linker is made by the formation of a sulfur-carbon (thioether) bond in the form, for instance, of R1-S-R2. Thioether can be made by either alkylation of a

0156thiol/mercaptan (-SH) group on one component such as the antigen or adjuvant with an alkylating group such as halide or epoxide on a second component such as the nanocarrier. Thioether linkers can also be formed by Michael addition of a thiol/mercaptan group on one component such as a antigen or adjuvant to an electron-deficient alkene group on a second component such as a polymer containing a maleimide group or vinyl sulfone group as the Michael acceptor. In another way, thioether linkers can be prepared by the radical thiol-ene reaction of a thiol/mercaptan group on one component such as a antigen or adjuvant with an alkene group on a second component such as a polymer or nanocarrier.

0157A hydrazone linker is made by the reaction of a hydrazide group on one component such as the antigen or adjuvant with an aldehyde/ketone chemistrygroup on the second component such as the nanocarrier.

0158A hydrazide linker is formed by the reaction of a hydrazine group on one component such as the antigen or adjuvant with a carboxylic acid group on the second component such as the nanocarrier. Such reaction is generally performed using chemistry similar to the formation of amide bond where the carboxylic acid is activated with an activating reagent.

0159An imine or oxime linker is formed by the reaction of an amine or N-alkoxyamine (or aminooxy) group on one component such as the antigen or adjuvant with an aldehyde or ketone group on the second component such as the nanocarrier.

0160An urea or thiourea linker is prepared by the reaction of an amine group on one component such as the antigen or adjuvant with an isocyanate or thioisocyanate group on the second component such as the nanocarrier. An amidine linker is prepared by the reaction of an amine group on one component such as the antigen or adjuvant with an imidoester group on the second component such as the nanocarrier.

0161An amine linker is made by the alkylation reaction of an amine group on one component such as the antigen or adjuvant with an alkylating group such as halide, epoxide, or sulfonate ester group on the second component such as the nanocarrier. Alternatively, an amine linker can also be made by reductive amination of an amine group on one component such as the antigen or adjuvant with an aldehyde or ketone group on the second component such as the nanocarrier with a suitable reducing reagent such as sodium cyanoborohydride or sodium triacetoxyborohydride.

0162A sulfonamide linker is made by the reaction of an amine group on one component such as the antigen or adjuvant with a sulfonyl halide (such as sulfonyl chloride) group on the second component such as the nanocarrier.

0163A sulfone linker is made by Michael addition of a nucleophile to a vinyl sulfone. Either the vinyl sulfone or the nucleophile may be on the surface of the nanoparticle or attached to the antigen or adjuvant.

0164The antigen or adjuvant can also be conjugated to the nanocarrier via non-covalent conjugation methods. For examples, a negative charged antigen or adjuvant can be conjugated to a positive charged nanocarrier through electrostatic adsorption. An antigen or adjuvant containing a metal ligand can also be conjugated to a nanocarrier containing a metal complex via a metal-ligand complex.

0165In embodiments, an antigen or adjuvant can be attached to a polymer, for example polylactic acid-block-polyethylene glycol, prior to the assembly of the synthetic nanocarrier or the synthetic nanocarrier can be formed with reactive or activatible groups on its surface. In the latter case, the antigen or adjuvant may be prepared with a group which is compatible with the attachment chemistry that is presented by the synthetic nanocarrier' s surface. In other embodiments, a peptide antigen can be attached to VLPs or liposomes using a suitable linker. A linker is a compound or reagent that capable of coupling two molecules together. In an embodiment, the linker can be a homobifuntional or heterobifunctional reagent as described in Hermanson, 2008. For example, an VLP or liposome synthetic nanocarrier containing a carboxylic group on the surface can be treated with a homobifunctional linker, adipic dihydrazide (ADH), in the presence of EDC to form the corresponding synthetic nanocarrier with the ADH linker. The resulting ADH linked synthetic nanocarrier is then conjugated with a peptide antigen containing an acid group via the other end of the ADH linker on NC to produce the corresponding VLP or liposome peptide conjugate.

0166For detailed descriptions of available conjugation methods, see Hermanson G T "Bioconjugate Techniques", 2nd Edition Published by Academic Press, Inc., 2008. In addition to covalent attachment the antigen or adjuvant can be coupled by adsorption to a pre-formed synthetic nanocarrier or it can be coupled by encapsulation during the formation of the synthetic nanocarrier.

0168Synthetic nanocarriers may be prepared using a wide variety of methods known in the art. For example, synthetic nanocarriers can be formed by methods as

0169nanoprecipitation, flow focusing using fluidic channels, spray drying, single and double emulsion solvent evaporation, solvent extraction, phase separation, milling, microemulsion procedures, microfabrication, nanofabrication, sacrificial layers, simple and complex coacervation, and other methods well known to those of ordinary skill in the art.

0170Alternatively or additionally, aqueous and organic solvent syntheses for monodisperse semiconductor, conductive, magnetic, organic, and other nanomaterials have been described (Pellegrino et al., 2005, Small, 1:48; Murray et al., 2000, Ann. Rev. Mat. Sci., 30:545; and Trindade et al., 2001, Chem. Mat., 13:3843). Additional methods have been described in the literature (see, e.g., Doubrow, Ed., "Microcapsules and Nanoparticles in Medicine and Pharmacy," CRC Press, Boca Raton, 1992; Mathiowitz et al., 1987, J. Control. Release, 5:13; Mathiowitz et al., 1987, Reactive Polymers, 6:275; and Mathiowitz et al., 1988, J. Appl. Polymer Sci., 35:755, US Patents 5578325 and 6007845; P. Paolicelli et al., "Surface- modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles" Nanomedicine. 5(6):843-853 (2010)).

0171Various materials may be encapsulated into synthetic nanocarriers as desirable using a variety of methods including but not limited to C. Astete et al., "Synthesis and

0172characterization of PLGA nanoparticles" J. Biomater. Sci. Polymer Edn, Vol. 17, No. 3, pp. 247-289 (2006); K. Avgoustakis "Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) Nanoparticles: Preparation, Properties and Possible Applications in Drug Delivery" Current Drug Delivery 1:321-333 (2004); C. Reis et al., "Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles" Nanomedicine 2:8- 21 (2006) ; P. Paolicelli et al., "Surface-modified PLGA-based Nanoparticles that can Efficiently

0173Associate and Deliver Virus-like Particles" Nanomedicine. 5(6):843-853 (2010). Other methods suitable for encapsulating materials, such as oligonucleotides, into synthetic nanocarriers may be used, including without limitation methods disclosed in United States Patent 6,632,671 to Unger (October 14, 2003).

0174In certain embodiments, synthetic nanocarriers are prepared by a nanoprecipitation process or spray drying. Conditions used in preparing synthetic nanocarriers may be altered to yield particles of a desired size or property (e.g., hydrophobicity, hydrophilicity, external morphology, "stickiness," shape, etc.). The method of preparing the synthetic nanocarriers and the conditions (e.g., solvent, temperature, concentration, air flow rate, etc.) used may depend on the materials to be coupled to the synthetic nanocarriers and/or the composition of the polymer matrix.

0175If particles prepared by any of the above methods have a size range outside of the desired range, particles can be sized, for example, using a sieve.

0176Elements of the inventive synthetic nanocarriers (such as moieties of which an immunofeature surface is comprised, targeting moieties, polymeric matrices, antigens, adjuvants, and the like) may be coupled to the overall synthetic nanocarrier, e.g., by one or more covalent bonds, or may be coupled by means of one or more linkers. Additional methods of functionalizing synthetic nanocarriers may be adapted from Published US Patent Application 2006/0002852 to Saltzman et al., Published US Patent Application

01772009/0028910 to DeSimone et al., or Published International Patent Application

0178WO/2008/127532 Al to Murthy et al.

0179Alternatively or additionally, synthetic nanocarriers can be coupled to

0180immunofeature surfaces, targeting moieties, adjuvants, various antigens, and/or other elements directly or indirectly via non-covalent interactions. In non-covalent embodiments, the non-covalent coupling is mediated by non-covalent interactions including but not limited to charge interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, hydrophobic interactions, TT stacking interactions, hydrogen bonding interactions, van der Waals interactions, magnetic interactions, electrostatic interactions, dipole-dipole interactions, and/or combinations thereof. Such couplings may be arranged to be on an external surface or an internal surface of an inventive synthetic nanocarrier. In embodiments, encapsulation and/or absorption is a form of coupling. A wide variety of the one or more second antigens (or additional antigens that are not coupled to the population of synthetic nanocarriers) may be incorporated into the dosage form, and may be incorporated in a wide variety of ways. Types of one or more second antigens (or additional antigens that are not coupled to the population of synthetic nanocarriers) suitable for use with the present invention have been discussed elsewhere herein.

0181There are a wide variety of ways of incorporating the one or more first or more second antigens (or additional antigens that are not coupled to the population of synthetic nanocarriers) into the inventive dosage form. In an embodiment, the one or more second antigens may be admixed into the dosage form together with the population of synthetic nanocarriers. For instance, in an embodiment, a vaccine that comprises the one or more second antigens may be admixed with the population of synthetic nanocarriers to form the inventive dosage forms. In embodiments, the inventive synthetic nanocarriers can be incorporated into the inventive dosage forms together with one or more first antigen that are different, similar or the same as the one or more second antigens in a wide variety of ways, including but not limited to: with or without adjuvant, utilizing or not utilizing another delivery vehicle, administered separately at a different time-point and/or at a different body location and/or by a different immunization route.

0182In embodiments, the populations of synthetic nanocarriers may be combined with the one or more second antigens (which may be incorporated in a wide variety of ways) to form dosage forms according to the present invention. The one or more second antigens may be provided in solution form, suspension form, powder form, etc., and may be provided as a vaccine formulation. For instance, in an embodiment, the one or more second antigen may be provided in the form of a hapten-carrier protein, oligosaccharide, oligosaccharide complex, oligosaccharide-carrier protein fusion, live attenuated, or recombinant virus vaccine formulation, and the population of synthetic nanocarriers admixed with the hapten- carrier protein, oligosaccharide, oligosaccharide complex, oligosaccharide-carrier protein fusion, live attenuated, or recombinant virus vaccine formulation, to form a multivalent vaccine dosage form (or increase the valency of the hapten-carrier protein or live attenuated virus vaccine formulations). In embodiments, the one or more second antigens can be comprised in a vaccine against Anthrax; Diphtheria, Tetanus and/or Pertussis; Haemophilus influenzae type B; Hepatitis B; Hepatitis A; Hepatitis C; Herpes zoster (shingles); Human Papillomavirus (HPV); Influenza; Japanese Encephalitis; Tick-borne Encephalitis; Measles, Mumps and/or Rubella; Meningococcal disease; Pneumococcal disease; Polio; Rabies; Rotavirus; Typhoid; Varicella; Vaccinia (Smallpox); or Yellow Fever. In other

0183embodiments, the one or more second antigens are comprised in a commercially available vaccine, including but not limited to, BIOTHRAX, DAPTACEL, INFANRIX, TRIPEDIA, TRIHIBIT, KINRIX, PEDIARIX, PENTACEL, PEDVAXHIB, ACTHIB, HIBERIX, COMVAX, HAVRIX, VAQTA, ENGERIX-B, RECOMBIVAX HB, TWINRIX,

ZOSTAVAX, GARDASIL, CERVARIX, FLUARIX, FLUVIRIN, FLUZONE,

FLULAVAL, AFLURIA, AGRIFLU, FLUMIST, JE-VAX, IXIARO, M-M-R II,

0186PROQUAD, MENOMUNE, MENACTRA, MENVEO, PNEUMOVAX 23, PREVNAR, PCV13, IPOL, IMOVAX RABIES, RABAVERT, ROTATEQ, ROTARIX, DECAVAC,

0187BOOSTRIX, ADACEL, TYPHIM VI, VIVOTIF BERNA, VARIVAX, ACAM2000 or YF- VAX.

0188In another embodiment, the population of synthetic nanocarriers may be combined with proteins taken from an infectious organism, such as human influenza A virus HA protein, either in proteinaceous form or in virus-like particles, to form a multivalent vaccine dosage form according to the invention. In another embodiment, the population of synthetic nanocarriers may be added to another population of synthetic nanocarriers that comprise the one or more second antigens to form a multivalent synthetic nanocarrier vaccine dosage form. In other embodiments, additional antigens beyond the one or more first and/or second antigens can be incorporated into the dosage form (through admixing, and other techniques disclosed herein or known conventionally). In embodiments, the inventive compositions provided herein comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15 or more different antigens.

0189In embodiments, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from a virus of a family of viruses shown below in Table 1. In another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from a virus of a species provided in Table 1. In still another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from an antigen provided in Table 1. Table 1: Viral Infectious Agents

0190Family Exemplary Species Exemplary Antigens

0191Adenoviridae adenovirus VI, VII, E1A, E3-19K, 52K Picornaviridae coxsackievirus, , VP1

0192hepatitis A virus Surface antigen

0193poliovirus, 3A protein, capsid protein

0194Rhinovirus (e.g., nucleocapsid, surface projection, and type 16) transmembrane proteins

0195Herpesviridae Herpes simplex Capsid proteins (e.g., UL6, UL18,

0196(type 1 and type 2) UL35, UL38, and UL19)

0197Varicella-zoster

0198virus Early antigen

0199Epstein-barr virus, Early antigen, capsid antigen

0200Human

0201cytomegalovirus Pp65, gB, p52

0202Human herpesvirus,

0203(e.g., type 8) Latent nuclear antigen- 1

0204Hepadnaviridae Hepatitis B virus surface antigen

0205Flaviviridae Hepatitis C virus, NS3, Envelop protein (e.g., E2

0206yellow fever virus, domain)

0207dengue virus,

0208West Nile virus

0209Retroviridae HIV gpl20, p24, and lipopeptides Gag (17- 35), Gag (253-284), Nef (66-97), Nef (116-145), and Pol (325-355); see Roberts et al., J. Immunol. Methods, 365(l-2):27-37, 2011

0210Orthomyxoviridae Influenza virus neuraminidase, surface antigen,

0211Measles virus,

0212Mumps virus

0213Nucleocapsid protein, matrix protein,

0214Parainfluenza virus

0215phosphoprotein, fusion protein,

0216Paramyxoviridae Respiratory

0217hemagglutinin, hemagglutinin- syncytial virus

0218neuraminidase, glycoprotein,

0219Human

0220metapneumovirus Human

0221Papillomaviridae papillomavirus (e.g.,

0222type 16 and 18) E6, E7, capsid antigen

0223Rhabdoviridae Rabies virus Envelope lipoprotein

0224Togaviridae Rubella virus Capsid protein

0225Paroviridae Human bocarivus, Capsid protein, non- structural protein

0226Parvovirus B19 (NS)

0227In embodiments, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from a bacteria of a genera of bacteria shown below in Table 2. In another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from a bacterial species provided in Table 2. In still another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from an antigen provided in Table 2.

0228Table 2: Bacterial Infectious Agents

0229Pathogenic

0230Bacterial Exemplary Species Exemplary Antigens Genera

0231Bordetella Bordetella pertussis pertussis toxin (PT), filamentous

0232hemagglutinin (FHA), pertactin (PRN), and fimbriae (FIM 2/3)

0233Borrelia Borrelia burgdorferi VlsE; DbpA and OspA

0234Brucella abortus Hia, PrpA, MltA, L7/L12, D15, 0187,

0235VirJ, Mdh, AfuA

0236Brucella Brucella canis L7/L12

0237Brucella melitensis Out membrane proteins such as Omp28

0238Brucella suis

0239Campylobacter Campylobacter jejuni; LPS, an 100-kD antigen

0240Chlamydia and Chlamydia pneumoniae See Richard et al., J. Infectious Chlamydophila Chlamydia trachomatis Diseases. 181:S521 (2000)

0241Chlamydophila psittaci Clostridium botulinum antigen types A, B, C, D, and E

0242Clostridium difficile FliC, FliD, and Cwp84 alpha-toxin, theta-toxin, fructose 1,6- biphosphate- aldolase (FBA),

0243Clostridium glyceraldehydes-3-phosphate

0244Clostridium perfringens dehydrogenase (GPD),

0245pyruvate:ferredoxin oxidoreductase (PFOR), elongation factor-G (EF-G), and a hypothetical protein (HP)

0246Clostridium tetani T toxin

0247Coryneb acterium Coryneb acterium diphtheriae Toxoid antigen

0248Enterococcus Enterococcus faecalis capsular polysaccharides

0249Enterococcus faecium

0250Escherichia Escherichia coli See Moriel et al., PNAS 107(20):9072- 9077 (2010)

0251Francisella Francisella tularensis See Havlasova et al., Proteomics

02522(7):857-867, 2002

0253Haemophilus Haemophilus influenzae capsular polysaccharides, Protein D,

0254Helicobacter Helicobacter pylori See Bumann et al., Proteomics

02554(10):2843-2843, 2004

0256Legionella Legionella pneumophila Mip

0257Leptospira Leptospira interrogans See Brown et al., Infect Immu

025859(5):1772-1777, 1991

0259Listeria Listeria monocytogenes nucleoprotein (NP)

0260Mycobacterium* Mycobacterium leprae

0261Mycobacterium tuberculosis RDl, PE35, PPE68, EsxA, EsxB, RD9, and EsxV

0262Mycobacterium ulcerans

0263Mycoplasma Mycoplasma pneumoniae Hsp70

0264Neisseria Neisseria gonorrhoeae

0265Neisseria meningitidis See Litt et al., J. Infectious Disease 190(8): 1488-1497, 2004

0266Pseudomonas Pseudomonas aeruginosa Lipopolysaccharides

0267Rickettsia Rickettsia rickettsii Surface antigen

0268Salmonella Salmonella typhi

0269Salmonella typhimurium

0270Shigella Shigella sonnei

0271Staphylococcus Staphylococcus aureus See Vytvtska et al., Proteomics

02722(5):580-590, 2002; Etz et al., PNAS 99(10):6573-6578; 2002

0273Staphylococcus epidermidis

0274Staphylococcus saprophyticus

0275Streptococcus Streptococcus agalactiae

0276Streptococcus pneumoniae Spl, Sp2, Sp3

0277Streptococcus pyogenes Lei et al., J. Infectious Disease

0278189(l):79-89, 2004

0279Treponema Treponema pallidum Glycerophosphodiester

0280Phosphodiesterase

0281Vibrio Vibrio cholerae Outer membrane proteins such as

0282OmpK

0283Yersinia Yersinia pestis Chaperone-usher protein, capsular protein (Fl), and V protein

0284In other embodiments, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from a fungus of a genera of fungi shown below in Table 3. In another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from a fungal species provided in Table 3. In still another embodiment, the one or more first antigens and/or one or more second antigens comprise or are obtained or derived from an antigen provided in Table 3. Table 3: Fungal Infectious Agents

0285<img file="EP2575773A2_D0002.tif" />

0286Combination of the population of synthetic nanocarriers and the one or more second antigens may be accomplished using traditional pharmaceutical mixing methods. These include liquid-liquid mixing in which two or more suspensions, containing a population of synthetic nanocarrier or the one or more second antigens, are directly combined or are brought together via one or more vessels containing diluent. As synthetic nanocarriers may also be produced or stored in a powder form, dry powder-powder mixing could be performed if the one or more second antigens are available in powder, as could the re- suspension of two or more powders in a common media. Depending on the properties and the interaction potential of the synthetic nanocarriers and the one or more second antigens, there may be advantages conferred to one or another route of mixing. Techniques suitable for use in practicing the present invention may be found in Handbook of Industrial Mixing: Science and Practice, Edited by Edward L. Paul, Victor A. Atiemo-Obeng, and Suzanne M. Kresta, 2004 John Wiley & Sons, Inc.; and Pharmaceutics: The Science of Dosage Form Design, 2nd Ed. Edited by M. E. Auten, 2001, Churchill Livingstone. In an embodiment, inventive synthetic nanocarriers are suspended in sterile saline solution for injection together with a preservative.

0287Doses of dosage forms contain varying amounts of populations of synthetic nanocarriers and varying amounts of one or more second antigens, according to the invention. The amount of synthetic nanocarriers and/or one or more second antigens present in the inventive dosage forms can be varied according to the nature of the antigens, the therapeutic benefit to be accomplished, and other such parameters. In embodiments, dose ranging studies can be conducted to establish optimal therapeutic amount of the population of synthetic nanocarriers and the amount of one or more second antigens to be present in the dosage form. In embodiments, the population of synthetic nanocarriers and the one or more second antigens are present in the dosage form in an amount effective to generate an immune response to the one or more first antigens and the one or more second antigens upon administration to a subject. It may be possible to determine amounts of the first, second, and/or subsequent antigens effective to generate an immune response using conventional dose ranging studies and techniques in subjects.

0288In embodiments, the inventive dosage forms can be formulated by admixing uncoupled adjuvants in the same vehicle or delivery system as the population of synthetic nanocarriers and the one or more second antigens. Such adjuvants may include, but are not limited to mineral salts, such as alum, alum combined with monphosphoryl lipid (MPL) A of Enterobacteria, such as Escherihia coli, Salmonella minnesota, Salmonella typhimurium, or Shigella flexneri or specifically with MPL® (AS04), MPL A of above-mentioned bacteria separately, saponins, such as QS-21,Quil-A, ISCOMs, ISCOMATRTX™, emulsions such as MF59™, Montanide® ISA 51 and ISA 720, AS02 (QS21+squalene+ MPL®), AS15, liposomes and liposomal formulations such as AS01, synthesized or specifically prepared microparticles and microcarriers such as bacteria-derived outer membrane vesicles (OMV) of N. gonorrheae, Chlamydia trachomatis and others, or chitosan particles, depot-forming agents, such as Pluronic® block co-polymers, specifically modified or prepared peptides, such as muramyl dipeptide, aminoalkyl glucosaminide 4- phosphates, such as RC529, or proteins, such as bacterial toxoids or toxin fragments. The doses of such other adjuvants can be determined using conventional dose ranging studies. In embodiments, adjuvant that is not coupled to the recited population synthetic nanocarriers may be the same or different from adjuvant that is coupled to the synthetic nanocarriers.

0289Typical inventive compositions that comprise synthetic nanocarriers may comprise inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate, or citrate) and pH adjustment agents (e.g., hydrochloric acid, sodium or potassium hydroxide, salts of citrate or acetate, amino acids and their salts) antioxidants (e.g., ascorbic acid, alpha-tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene9- 10 nonyl phenol, sodium desoxycholate), solution and/or cryo/lyo stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic adjustment agents (e.g., salts or sugars), antibacterial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g.,

0290polydimethylsilozone), preservatives (e.g., thimerosal, 2-phenoxyethanol, EDTA), polymeric stabilizers and viscosity- adjustment agents (e.g., polyvinylpyrrolidone, poloxamer 488, carboxymethylcellulose) and co-solvents (e.g., glycerol, polyethylene glycol, ethanol).

0291Compositions according to the invention comprise inventive synthetic nanocarriers in combination with pharmaceutically acceptable excipients. The compositions may be made using conventional pharmaceutical manufacturing and compounding techniques to arrive at useful dosage forms. Techniques suitable for use in practicing the present invention may be found in Handbook of Industrial Mixing: Science and Practice, Edited by Edward L. Paul, Victor A. Atiemo-Obeng, and Suzanne M. Kresta, 2004 John Wiley &

0292Sons, Inc.; and Pharmaceutics: The Science of Dosage Form Design, 2nd Ed. Edited by M. E. Auten, 2001, Churchill Livingstone. In an embodiment, inventive synthetic nanocarriers are suspended in sterile saline solution for injection together with a preservative.

0293It is to be understood that the compositions of the invention can be made in any suitable manner, and the invention is in no way limited to compositions that can be produced using the methods described herein. Selection of an appropriate method may require attention to the properties of the particular moieties being associated.

0294In some embodiments, inventive synthetic nanocarriers are manufactured under sterile conditions or are terminally sterilized. This can ensure that resulting composition are sterile and non-infectious, thus improving safety when compared to non-sterile

0295compositions. This provides a valuable safety measure, especially when subjects receiving synthetic nanocarriers have immune defects, are suffering from infection, and/or are susceptible to infection. In some embodiments, inventive synthetic nanocarriers may be lyophilized and stored in suspension or as lyophilized powder depending on the formulation strategy for extended periods without losing activity.

0296The inventive compositions may be administered by a variety of routes of administration, including but not limited to subcutaneous, intramuscular, intradermal, oral, intranasal, transmucosal, sublingual, rectal, ophthalmic, transdermal, transcutaneous or by a combination of these routes.

0297Doses of dosage forms contain varying amounts of synthetic nanocarriers or populations thereof and varying amounts of antigens and/or adjuvants, according to the invention. The amount of synthetic nanocarriers and/or antigens and/or adjuvants present in the inventive dosage forms can be varied according to the nature of the antigens, the therapeutic benefit to be accomplished, and other such parameters. In embodiments, dose ranging studies can be conducted to establish optimal therapeutic amount of the synthetic nanocarriers or population thereof and the amount of antigens and/or adjuvant to be present in the dosage form. In embodiments, the synthetic nanocarriers and the antigens and/or adjuvants are present in the dosage form in an amount effective to generate an immune response to the antigens upon administration to a subject. It may be possible to determine amounts of the antigens and/or adjuvants effective to generate an immune response using conventional dose ranging studies and techniques in subjects. Inventive dosage forms may be administered at a variety of frequencies. In a preferred embodiment, at least one administration of the dosage form is sufficient to generate a pharmacologically relevant response. In more preferred embodiment, at least two administrations, at least three administrations, or at least four administrations, of the dosage form are utilized to ensure a pharmacologically relevant response.

0298The compositions and methods described herein can be used to induce, enhance, suppress, modulate, direct, or redirect an immune response. The compositions and methods described herein can be used in the diagnosis, prophylaxis and/or treatment of conditions such as cancers, infectious diseases, metabolic diseases, degenerative diseases, autoimmune diseases, inflammatory diseases, immunological diseases, or other disorders and/or conditions. The compositions and methods described herein can also be used for the prophylaxis or treatment of an addiction, such as an addiction to nicotine or a narcotic. The compositions and methods described herein can also be used for the prophylaxis and/or treatment of a condition resulting from the exposure to a toxin, hazardous substance, environmental toxin, or other harmful agent. The subjects provided herein can have or be at risk of having cancer. Cancers include, but are not limited to, breast cancer; biliary tract cancer; bladder cancer; brain cancer including glioblastomas and medulloblastomas; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous leukemia, e.g., B Cell CLL; T- cell acute lymphoblastic leukemia/lymphoma; hairy cell leukemia; chronic myelogenous leukemia, multiple myeloma; AIDS-associated leukemias and adult T-cell

0299leukemia/lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma; ovarian cancer including those arising from epithelial cells, stromal cells, germ cells and

0300mesenchymal cells; pancreatic cancer; prostate cancer; rectal cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer including melanoma, Merkel cell carcinoma, Kaposi's sarcoma, basal cell carcinoma, and squamous cell cancer; testicular cancer including germinal tumors such as seminoma, non-seminoma (teratomas, choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer including thyroid adenocarcinoma and medullar carcinoma; and renal cancer including adenocarcinoma and Wilms tumor.

0301The subjects provided herein can have or be at risk of having an infection or infectious disease. Infections or infectious diseases include, but are not limited to, viral infectious diseases, such as AIDS, Chickenpox (Varicella), Common cold, Cytomegalovirus Infection, Colorado tick fever, Dengue fever, Ebola hemorrhagic fever, Hand, foot and mouth disease, Hepatitis, Herpes simplex, Herpes zoster, HPV, Influenza (Flu), Lassa fever, Measles, Marburg hemorrhagic fever, Infectious mononucleosis, Mumps, Norovirus, Poliomyelitis, Progressive multifocal leukencephalopathy, Rabies, Rubella, SARS,

0302Smallpox (Variola), Viral encephalitis, Viral gastroenteritis, Viral meningitis, Viral pneumonia, West Nile disease and Yellow fever; bacterial infectious diseases, such as Anthrax, Bacterial Meningitis, Botulism, Brucellosis, Campylobacteriosis, Cat Scratch Disease, Cholera, Diphtheria, Epidemic Typhus, Gonorrhea, Impetigo, Legionellosis, Leprosy (Hansen's Disease), Leptospirosis, Listeriosis, Lyme disease, Melioidosis,

0303Rheumatic Fever, MRSA infection, Nocardiosis, Pertussis (Whooping Cough), Plague, Pneumococcal pneumonia, Psittacosis, Q fever, Rocky Mountain Spotted Fever (RMSF), Salmonellosis, Scarlet Fever, Shigellosis, Syphilis, Tetanus, Trachoma, Tuberculosis, Tularemia, Typhoid Fever, Typhus and Urinary Tract Infections; parasitic infectious diseases, such as African trypanosomiasis, Amebiasis, Ascariasis, Babesiosis, Chagas Disease, Clonorchiasis, Cryptosporidiosis, Cysticercosis, Diphyllobothriasis,

0304Dracunculiasis, Echinococcosis, Enterobiasis, Fascioliasis, Fasciolopsiasis, Filariasis, Free- living amebic infection, Giardiasis, Gnathostomiasis, Hymenolepiasis, Isosporiasis, Kala- azar, Leishmaniasis, Malaria, Metagonimiasis, Myiasis, Onchocerciasis, Pediculosis, Pinworm Infection, Scabies, Schistosomiasis, Taeniasis, Toxocariasis, Toxoplasmosis, Trichinellosis, Trichinosis, Trichuriasis, Trichomoniasis and Trypanosomiasis; fungal infectious disease, such as Aspergillosis, Blastomycosis, Candidiasis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Tinea pedis (Athlete's Foot) and Tinea cruris; prion infectious diseases, such as Alpers' disease, Fatal Familial Insomnia, Gerstmann-Straussler- Scheinker syndrome, Kuru and Variant Creutzfeldt-Jakob disease.

EXAMPLES

0306Example 1: Synthetic Nanocarriers with Covalently Coupled Adjuvant

0307Nanocarriers comprising PLGA-R848, PLA-PEG-N3, and ova peptide were prepared via double emulsion method wherein the ova peptide was encapsulated in the nanocarriers.

0308The polyvinyl alcohol (Mw = 11 KD - 31 KD, 87-89% partially hydrolyzed) was purchased from JT Baker. Ovalbumin peptide 323-339 was obtained from Bachem

0309Americas Inc. (3132 Kashiwa Street, Torrance CA 90505. Part # 4065609). PLGA-R848, and PLA-PEG-N3 conjugates were synthesized and purified.

0310The above materials were used to prepare the following solutions:

03111. PLGA-R848 conjugate in methylene chloride @ 100 mg/mL

03122. PLA-PEG-N3 in methylene chloride @ 100 mg/mL

03133. Ovalbumin peptide 323 - 339 in 0.13N HC1 @ 70 mg/mL

03144. Polyvinyl alcohol in lOOmM pH 8 phosphate buffer @50 mg/mL

0315Solution #1 (0.75 mL) and solution #2 (0.25 mL) were combined and solution #3 (O.lmL) or 0.13N HC1 (O.lmL) was added in a small vessel and the mixture was sonicated at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. To this emulsion was added solution # 4 (2.0 mL) and sonication at 30% amplitude for 40 seconds using the Branson Digital Sonifier 250 formed the second emulsion. This was added to a stirring beaker containing a 70mM pH 8 phosphate buffer solution (30 mL), and this mixture was stirred at room temperature for 2 hours to form the nanocarriers.

0316To wash the nanocarriers, a portion of the nanoparticle dispersion (26.5mL) was transferred to a 50mL centrifuge tube and spun at 9500rpm (13,800g) for one hour at 4°C, the supernatant was removed, and the pellet was re-suspended in 26.5 mL of phosphate buffered saline. The centrifuge procedure was repeated and the pellet was re-suspended in 8.3g of phosphate buffered saline for a final nanocarrier dispersion of about 10 mg/mL.

0317To a suspension of the synthetic nanocarriers (10 mg/mL in PBS (pH 7.4 buffer), 5 mL, containing about 12.5 mg (MW: 20, 000; 0.000625 mmol) of PLA-PEG-N3) was added L2 derived peptide H-Ala-Thr-Gln-Leu-Tyr-Lys-Thr-Cys-Lys-Gln-Ala-Gly-Thr-Cys- Pro-Pro-Asp-Ile-Ile-Pro-Lys-Val-X (SEQ ID NO:2); wherein X is a linker group

0318comprising an acetylene linker (33 mg) with gentle stirring. A solution of sodium ascorbate (100 mM in H20, 0.3 mL) was added, followed by CuS04 solution (10 mM in water, 0.6 mL). The resulting light yellow suspension was stirred at 20 C for 15 h and additional CuS04 solution (0.3 mL) and sodium ascorbate solution (0.15 mL) were added. The suspension was stirred for 5 h at 20 C and diluted with PBS buffer (pH 7.4) to 10 mL and centrifuged to remove the supernatant. The residual nanocarrier pellets were washed twice with PBS buffer. The washed nanocarriers were then re-suspended in 5 mL of PBS buffer and stored frozen. The conjugation of L2 peptide on the surface of the synthetic

0319nanocarriers was confirmed by HPLC analysis of the digested nanocarriers and by bioassay.

0320Example 2: Composition with Synthetic Nanocarriers and Uncoupled Antigen

0321(Prophetic)

0322A 4 mL portion of the synthetic nanocarrier suspension from Example 1 containing 8 mg of L2 substituted nanocarriers is centrifuged to settle the particles. The supernatant is discarded and a 0.5-mL suspension of Gardasil®, Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine containing purified virus-like particles (VLPs) of the major capsid (LI) protein of HPV Types 6, 11, 16, and 18 is added. The combination vaccine is agitated to re-suspend the nanocarriers and the resulting suspension is stored at - 20°C prior to use. Example 3: Synthetic Nanocarriers with Non-Covalently Coupled Adjuvant

0323[Prophetic]

0324DNA containing cationic disulfide PRINT nanocarriers are produced by the method described in the patent application of DeSimone, WO2008118861, example 16 with the exception that the ssDNA-fluorescein of example 16 is replaced by the phosphorothioated DNA CpG 7909. After isolation, the cationic nanocarriers are suspended in 1.0 mL of PBS solution containing 10 mg/mL of heparin. After stirring at room temperature for 2 hours, the nanocarriers are isolated by centrifugation and are washed twice with PBS by centrifugation and decantation. The nanocarriers containing CpG 7909 with surface adsorbed heparin are re-suspended in 1.0 mL of PBS and are stored at -20°C prior to use.

0325Example 4: Composition with Synthetic Nanocarriers and Uncoupled Antigen (Prophetic)

0326A 1 mL portion of the synthetic nanocarrier suspension from Example 3 containing 10 mg of heparin substituted nanocarriers is centrifuged to settle the particles. The supernatant is discarded and a 1-mL suspension of Recombivax HB® or Engerix-B®, human hepatitis B Virus (HBV) vaccines containing purified proteinaceous particles consisting of the major surface antigen (HBsAg) protein of HBV is added. The combination vaccine is agitated to re-suspend the nanocarriers and the resulting suspension is stored at -20°C prior to use. A similar process is used to combine the heparin-substituted nanocarriers of

0327Example 3 with a 1 mL suspension of bivalent vaccine against human hepatitis A and B viruses (Twinrix®), consisting of purified HBsAg and inactivated human hepatitis A virus.

0328Example 5: Synthetic Nanocarriers with Covalently Coupled Adjuvant [Prophetic] Example 5A: Preparation of R848 covalently attached to a thiol

0329<img file="EP2575773A2_D0003.tif" />

0330<img file="EP2575773A2_D0004.tif" />

03313,3'-dithio bis-propionic acid (cat # 109010) is purchased from Aldrich Chemical Company. R848 is synthesized at Selecta Biosciences. A solution of 3,3'-dithio bis- propionic acid (2.10 gm, 1.0 X 10"2 moles) and HBTU (15.2 g, 4 X 10"2 moles) in EtOAc (450 mL) is stirred at room temperature under argon for 45 min. Compound R848 (6.28 g, 2 X 10"2 moles)) is added, followed by DIPEA (20.9 mL, 1.2 X 10"1 moles). The mixture is stirred at room temperature for 6 h and then at 50-55 °C for 15 h. After cooling, the mixture is washed with 1% citric acid solution (2x40 mL), water (40 mL) and brine solution (40 mL). The solution is dried over Na2S04 (10 g) and, after filtration, the ethyl acetate is removed under vacuum. The product is recrystallized from 2-methoxyethanol to provide 6.5 gm (78%) of a white solid product.

0332The disulfide from above (5.0 gm) is dissolved in chloroform (200 mL) and the solution is treated with dithiothreitol (1.0 gm). After stirring at room temperature for 2 hours, the chloroform solution is washed with water (100 mL) and is then dried over sodium sulfate. After filtration to remove the drying agent, the chloroform is removed under vacuum and the solid remaining is purified by chromatography on silica using 10% methanol in methylene chloride as eluent. The fractions containing the thiol -R848 conjugate are pooled and evaporated to give 3.5 gm (70%) of the thiol - R848 conjugate as a white solid.

0333Example 5B: Preparation of Nanocarriers

0334Gold synthetic nanocarriers are prepared as described in example (a) of US patent application 2009 0104268 Al to Midatech Limited except that peptide BCl lis replaced with the thiol R848 conjugate from Example 5A above and the oligosaccharide antigens are replaced with L2 derived peptide H-Ala-Thr-Gln-Leu-Tyr-Lys-Thr-Cys-Lys-Gln-Ala-Gly- Thr-Cys-Pro-Pro-Asp-Ile-Ile-Pro-Lys-Val-X (SEQ ID NO:2); wherein X is a linker group comprising a cysteine residue. After washing and concentration as described in the

0335Midatech application, the particles weighing 1.0 mg are used as described in Example 6.

0336Example 6: Composition with Synthetic Nanocarriers and Uncoupled Antigen

0337(Prophetic)

0338A 1.0 mg portion of the gold nanocarriers from Example 5 are added to a lmL of oral suspension of live recombinant anti-rotaviral vaccine Rotarix® against gastroenteritis induced by type Gl and non-Gl (G3, G4, and G9) rotavirus types. The combination oral vaccine is agitated to re-suspend the nanocarriers and the resulting suspension is stored at - 20°C prior to use as a combination oral vaccine.

0339Example 7: Synthetic Nanocarriers with T-helper Antigen and Adjuvant

0340Ovalbumin peptide 323-339 amide acetate salt, was purchased from Bachem

0341Americas Inc. (3132 Kashiwa Street, Torrance CA 90505. Product code 4065609.) PLGA- R848, poly-D/L-lactide-co-glycolide, 4-amino-2-(ethoxymethyl)-a,a-dimethyl-lH- imidazo[4,5-c]quinoline-l-ethanol amide of approximately 7,000 Da made from PLGA of 3:1 lactide to glycolide ratio and having approximately 8.5% w/w conjugated resiquimod content was custom manufactured at Princeton Global Synthesis (300 George Patterson Drive #206, Bristol, PA 19007.) PLA-PEG-C6-N3, block co-polymer consisting of a poly- D/L-lactide (PLA) block of approximately 23000 Da and a polyethylene glycol (PEG) block of approximately 2000 Da that is terminated by an amide-conjugated C6H12 linker to an azide, was synthesized by conjugating HO-PEG-COOH to an amino-C6H12-azide and then generating the PLA block by ring-opening polymerization of the resulting HO-PEG-C6-N3 with dl-lactide. Polyvinyl alcohol PhEur, USP (85-89% hydrolyzed, viscosity of 3.4-4.6 mPa.s) was purchased from EMD Chemicals Inc. (480 South Democrat Road Gibbstown, NJ 08027. Part Number 4-88).

0342Solutions were prepared as follows:

0343Solution 1: Ovalbumin peptide 323-339 @ 20mg/mL was prepared in 0.13N HC1 at room temperature.

0344Solution 2: PLGA-R848 @ 50 mg/mL and PLA-PEG-C6-N3 @ 50 mg/mL in dichloromethane was prepared by dissolving each separately at 100 mg/mL in

0345dichloromethane then combining in equal parts by volume.

0346Solution 3: Polyvinyl alcohol @ 50 mg/mL in 100 mM in lOOmM phosphate buffer, pH 8

0347Solution 4: 70 mM phosphate buffer, pH 8

0348A primary (Wl/O) emulsion was first created using Solution 1 and Solution 2. Solution 1 (0.2 mL) and Solution 2 (1.0 mL) were combined in a small glass pressure tube and sonicated at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. A secondary (W1/0/W2) emulsion was then formed by adding Solution 3 (2.0 mL) to the primary emulsion, vortexing to create a course dispersion, and then sonicating at 30% amplitude for 40 seconds using the Branson Digital Sonifier 250.

0349The secondary emulsion was added to an open 50 mL beaker containing 70 mM phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow the dichloromethane to evaporate and the nanocarriers to form in suspension. A portion of the suspended nanocarriers was washed by transferring the nanocarrier suspension to a centrifuge tube, spinning at 21,000 rcf for 45 minutes, removing the supernatant, and re- suspending the pellet in phosphate buffered saline. This washing procedure was repeated, and then the pellet was re-suspended in phosphate buffered saline to achieve a nanocarrier suspension having a nominal concentration of 10 mg/mL on a polymer basis. Two identical batches were created and then combined to form a single homogenous suspension at which was stored frozen at -20°C until further use.

0350Table 4: Nanocarrier Characterization

0351Nanocarrier Effective TLR Agonist, % Antigen, % w/w

0352Diameter (nm) w/w

0353209 R848, 4.2 Ova 323-339 peptide, 2.4 Example 8: Immunization with Synthetic Nanocarriers with Coupled Antigen and Free Protein Without Admixed Adjuvant Materials and Methods

0354(1) Nanocarriers with surface PEG-C6-N3 containing PLGA-R848 and Ova- peptide, prepared as above in Example 7, 7 mg/mL suspension in PBS.

0355(2) M2e peptide modified with an alkyne linker attached to C-terminal Gly; CS Bio Co, Catalog No. CS4956, Lot: H308, MW 2650, TFA salt; Sequence:

0356H-Met-Ser-Leu-Leu-Thr-Glu-Val-Glu-Thr-Pro-Thr-Arg-Asn-Glu-Trp-Glu-Cys-Arg- Cys-Ser-Asp-Gly-Gly-NHCH2CCH (SEQ ID NO:3)

0357(3) Catalysts: CuS04, 100 mM in DI water; THPTA ligand, 200 mM in DI water; sodium ascorbate, 200 mM in DI water freshly prepared.

0358(4) pH 7.4 PBS buffer.

0359The NC suspension (7 mg/mL, 4 mL) was concentrated to ca. 1 mL in volume by centrifuge. A solution of M2e peptide (20 mg) in 2 mL PBS buffer was added. A pre- mixed solution of 0.2 mL of CuS04 (100 mM) and 0.2 mL of THPTA ligand (200 mM) was added, followed by 0.4 mL of sodium ascorbate (200 mM). The resulting light yellow suspension was stirred in dark at ambient room temperature for 18 h. The suspension was then diluted with PBS buffer to 10 mL and centrifuged to remove the supernatant. The NC- M2e conjugates were further pellet washed twice with 10 mL PBS buffer and resuspended in pH 7.4 buffer at final concentration of ca. 6 mg/mL (ca. 4 mL) and stored at 4°C.

0360Results

0361Antibody titers in mice immunized with a combination of NC-M2e and free hemagglutinin from H5N1 avian influenza strain (Vietnam) were measured. NC-M2e contained OP-II T-helper peptide (2.4%) and R848 adjuvant (4.2%). Each bar represents the titer against antigen. Five animals per group were immunized s.c. with 120 μg of NC and 10 μg of H5 hemaggutinin per injection, 2 times with 3-wk intervals. Titers for day 33 after the first immunization are shown (ELISA against PLA-PEG-M2e and H5

0362hemagglutinin, respectively). The results show that immunization with a combination of NC carrying an antigen admixed to a free protein without an admixed adjuvant results in generation of antibodies to both NC-carried antigen and to a free protein. When a NC containing surface M2e peptide from influenza A virus (ectodomain of M2 matrix protein, amino acids 2-27) was admixed to free influenza A virus hemagglutinin protein and used for animal immunization, a strong humoral response was induced in all animals against both M2e peptide and hemagglutinin (Fig. 1). No reactivity was detected in the sera of preimmune mice.

0363Example 9: Immunization with Synthetic Nanocarriers with Coupled Antigen and Free Protein with Admixed Adjuvant

0364Materials and Methods

0365(1) Nanocarriers with surface PEG-C6-N3 containing PLGA-R848 and Ova- peptide, prepared as above in Example 7, 7 mg/mL suspension in PBS.

0366(2) M2e peptide modified with an alkyne linker attached to C-terminal Gly; CS

0367Bio Co, Catalog No. CS4956, Lot: H308, MW 2650, TFA salt; Sequence:

0368H-Met-Ser-Leu-Leu-Thr-Glu-Val-Glu-Thr-Pro-Thr-Arg-Asn-Glu-Trp-Glu-Cys-Arg- Cys-Ser-Asp-Gly-Gly-NHCH2CCH (SEQ ID NO:3).

0369(3) Catalysts: CuS04, 100 mM in DI water; THPTA ligand, 200 mM in DI water; sodium ascorbate, 200 mM in DI water freshly prepared.

0370(4) pH 7.4 PBS buffer.

0371The NC suspension (7 mg/mL, 4 mL) was concentrated to ca. 1 mL in volume by centrifuge. A solution of M2e peptide (20 mg) in 2 mL PBS buffer was added. A pre- mixed solution of 0.2 mL of CuS04 (100 mM) and 0.2 mL of THPTA ligand (200 mM) was added, followed by 0.4 mL of sodium ascorbate (200 mM). The resulting light yellow suspension was stirred in dark at ambient room temperature for 18 h. The suspension was then diluted with PBS buffer to 10 mL and centrifuged to remove the supernatant. The NC- M2e conjugates were further pellet washed twice with 10 mL PBS buffer and resuspended in pH 7.4 buffer at final concentration of ca. 6 mg/mL (ca. 4 mL) and stored at 4°C.

0372Results

0373Antibody titers in mice immunized with a combination of NC-M2e and free hemagglutinin from H5N1 avian influenza strain (Vietnam) admixed with 80 μg of alum. NC-M2e contained OP-II T-helper peptide (2.4%) and R848 adjuvant (4.2%). Each bar represents the titer against antigen. Five animals per group were immunized s.c. with 120 μg of NC and 10 μg of H5 hemaggutinin per injection, 2 times with 3-wk intervals. Titers for day 33 after the first immunization are shown (ELISA against PLA-PEG-M2e and H5 hemagglutinin, respectively).

0374The results show that immunization with a combination of a NC carrying an antigen admixed to a second antigen (free protein) with an admixed adjuvant results in generation of antibodies to both NC-carried antigen and to the second antigen. When a NC containing surface M2e peptide from influenza A virus (ectodomain of M2 matrix protein, amino acids 2-27) was admixed to free influenza A virus hemagglutinin protein and used for animal immunization admixed to alum (Imject Alum, Pierce), a strong humoral response was induced in all animals against both M2e peptide and hemagglutinin (Fig. 2). No reactivity was detected in the sera of preimmune mice. Example 10: Immunization with Synthetic Nanocarriers with Coupled Antigen and Virus Vaccine and Adjuvant

0375Materials and Methods

0376(1) Nanocarriers with surface PEG-C6-N3 containing PLGA-R848 and Ova- peptide, prepared as above in Example 7, 7 mg/mL suspension in PBS.

0377(2) M2e peptide modified with an alkyne linker attached to C-terminal Gly; CS Bio Co, Catalog No. CS4956, Lot: H308, MW 2650, TFA salt; Sequence:

0378H-Met-Ser-Leu-Leu-Thr-Glu-Val-Glu-Thr-Pro-Thr-Arg-Asn-Glu-Trp-Glu-Cys-Arg- Cys-Ser-Asp-Gly-Gly-NHCH2CCH (SEQ ID NO:3).

0379(3) Catalysts: CuS04, 100 mM in DI water; THPTA ligand, 200 mM in DI water; sodium ascorbate, 200 mM in DI water freshly prepared.

0380(4) pH 7.4 PBS buffer.

0381The NC suspension (7 mg/mL, 4 mL) was concentrated to ca. 1 mL in volume by centrifuge. A solution of M2e peptide (20 mg) in 2 mL PBS buffer was added. A pre- mixed solution of 0.2 mL of CuS04 (100 mM) and 0.2 mL of THPTA ligand (200 mM) was added, followed by 0.4 mL of sodium ascorbate (200 mM). The resulting light yellow suspension was stirred in dark at ambient room temperature for 18 h. The suspension was then diluted with PBS buffer to 10 mL and centrifuged to remove the supernatant. The NC- M2e conjugates were further pellet washed twice with 10 mL PBS buffer and resuspended in pH 7.4 buffer at final concentration of ca. 6 mg/mL (ca. 4 mL) and stored at 4°C.

0382Results

0383Antibody titers in mice immunized with a combination of NC-M2e and beta- propiolactone-inactivated influenza A virus HlNl (HlNl New Caledonia/20/99/ IVR 116) admixed with 80 μg of alum were measured. NC-M2e contained OP-II T-helper peptide (2.4%) and R848 adjuvant (4.2%). Each bar represents the titer against antigen. Five animals per group were immunized s.c. with 120 μg of NC and 1 μg of inactivated, thimerosal-containing HlNl New Caledonia per injection, 2 times with 3-wk intervals.

0384Titers for day 33 after the first immunization are shown (ELISA against PLA-PEG-M2e and HlNl New Caledonia, respectively).

0385The results show that immunization with a combination of NC carrying an antigen admixed with an inactivated virus vaccine and an adjuvant results in generation of antibodies to both NC-carried antigen and an inactivated virus. When a NC containing surface M2e peptide from influenza A virus (ectodomain of M2 matrix protein, amino acids 2-27) was admixed to inactivated influenza A virus HlNl and used for animal

0386immunization admixed to alum (Imject Alum, Pierce), a strong humoral response was induced in all animals against both M2e peptide and inactivated influenza A virus HlNl (Fig. 3). No reactivity was detected in the sera of preimmune mice.

0387Example 11: Immunization with Synthetic Nanocarriers with Coupled Antigen and Recombinant Vaccine with Adjuvant

0388Materials and Methods

0389(1) Nanocarriers with surface PEG-C6-N3 containing PLGA-R848 and Ova- peptide, prepared as above in Example 7, 7 mg/mL suspension in PBS.

0390(2) HPV16 L2 peptide modified with an alkyne linker attached to C-terminal

0391Lys amino group; Bachem Americas, Inc, Lot B06055, MW 2595, TFA salt; Sequence:

0392H-Ala-Thr-Gln-Leu-Tyr-Lys-Thr-Cys-Lys-Gln-Ala-Gly-Thr-Cys-Pro-Pro-Asp-Ile- Ile-Pro-Lys-Val-Lys(5-hexynoyl)-NH2(with Cys-Cys disulfide bond) (SEQ ID NO:2). (3) Catalysts: CuS04, 100 niM in DI water; THPTA ligand, 200 niM in DI water; sodium ascorbate, 200 mM in DI water freshly prepared.

0393(4) pH 7.4 PBS buffer.

0394The NC suspension (7 mg/mL, 4 mL) was concentrated to ca. 1 mL in volume by centrifuge. A solution of L2 peptide (20 mg) in 2 mL PBS buffer was added. A pre-mixed solution of 0.2 mL of CuS04 (100 mM) and 0.2 mL of THPTA ligand (200 mM) was added, followed by 0.4 mL of sodium ascorbate (200 mM). The resulting light yellow suspension was stirred in dark at ambient room temperature for 18 h. The suspension was then diluted with PBS buffer to 10 mL and centrifuged to remove the supernatant. The NC- L2 conjugates were further pellet washed twice with 10 mL PBS buffer and resuspended in pH 7.4 buffer at final concentration of ca. 6 mg/mL (ca. 4 mL) and stored at 4°C.

0395Results

0396Antibody titers in mice immunized with a combination of NC-L2-peptide and HBsAg strain ayw produced in the yeast Saccharomyces cerevisiae admixed with 80 μg of alum were measured. NC-L2-peptide contained OP-II T-helper peptide (2.4%) and R848 adjuvant (4.2%). Each bar represents the titer against antigen indicated. Five animals per group were immunized s.c. with 120 μg of NC and 0.6 μg of recombinant HBsAg, per injection, 2 times with 3-wk intervals. Titers for day 33 after the first immunization are shown (ELISA against PLA-PEG-L2 and HBsAg ayw, respectively).

0397The results show that immunization with a combination of a NC carrying an antigen admixed to a recombinant vaccine and an adjuvant results in generation of antibodies to both NC-carried antigen and to an inactivated virus. When a NC containing surface L2 peptide from HPV-16 virus minor capsid L2 protein (amino acids 17-36) was admixed to recombinant hepatitis B surface antigen (HBsAg) and used for animal immunization admixed to alum (Imject Alum, Pierce), a strong humoral response was induced in all animals against both L2 peptide and recombinant HBsAg (Fig. 4). No reactivity was detected in the sera of preimmune mice.

Every citation, both ways

Citations
Document	Relation	Office	Cited during
WO2007098254A2	Cites	World Intellectual Property Organization (WIPO)	Search report
WO2009109428A2	Cites	World Intellectual Property Organization (WIPO)	Search report
WO2010042863A1	Cites	World Intellectual Property Organization (WIPO)	Search report
WO2010042870A1	Cites	World Intellectual Property Organization (WIPO)	Search report
US2010092425A1	Cites	United States of America	Search report

114 members in 17 offices

This recordMember, by publication datePriority claim7 more offices are in the list below

Priority claims9

Priority claims
Document	Office	Kind	Date
348717P	United States of America	–	2010-05-26
348713P	United States of America	–	2010-05-26
348728P	United States of America	–	2010-05-26
34871710	United States of America	P	2010-05-26
34871310	United States of America	P	2010-05-26
34872810	United States of America	P	2010-05-26
358635P	United States of America	–	2010-06-25
35863510	United States of America	P	2010-06-25
2011038218	United States of America	W	2011-05-26

Members114

Family members, oldest first
Document	Office	Kind
CA2798323A1	Canada	A1	2011-12-01
CA2798493A1	Canada	A1	2011-12-01
CA2798739A1	Canada	A1	2011-12-01
CA2798994A1	Canada	A1	2011-12-01
US2011293700A1	United States of America	A1	2011-12-01
US2011293701A1	United States of America	A1	2011-12-01
US2011293723A1	United States of America	A1	2011-12-01
WO2011150240A1	World Intellectual Property Organization (WIPO)	A1	2011-12-01
WO2011150249A1	World Intellectual Property Organization (WIPO)	A1	2011-12-01
WO2011150258A1	World Intellectual Property Organization (WIPO)	A1	2011-12-01
WO2011150264A2	World Intellectual Property Organization (WIPO)	A2	2011-12-01
US2012027806A1	United States of America	A1	2012-02-02
AU2011258147A1	Australia	A1	2012-11-01
AU2011258156A1	Australia	A1	2012-11-08
AU2011258165A1	Australia	A1	2012-11-08
AU2011258171A1	Australia	A1	2012-11-08
IL222680A0	Israel	A0	2012-12-31
IL222680D0	Israel	D0	2012-12-31
IL222722A0	Israel	A0	2012-12-31
IL222722D0	Israel	D0	2012-12-31
IL222724A0	Israel	A0	2012-12-31
IL222724D0	Israel	D0	2012-12-31
IL222725A0	Israel	A0	2012-12-31
IL222725D0	Israel	D0	2012-12-31
MX2012013713A	Mexico	A	2013-01-28
MX2012013714A	Mexico	A	2013-01-28
MX2012013715A	Mexico	A	2013-01-28
MX2012013716A	Mexico	A	2013-01-28
CN102905728A	China	A	2013-01-30
CN102905729A	China	A	2013-01-30
CN102917731A	China	A	2013-02-06
WO2011150264A3	World Intellectual Property Organization (WIPO)	A3	2013-04-04
EP2575773A2This record	European Patent Office (EPO)	A2	2013-04-10
EP2575876A1	European Patent Office (EPO)	A1	2013-04-10
EP2575886A1	European Patent Office (EPO)	A1	2013-04-10
EP2582393A1	European Patent Office (EPO)	A1	2013-04-24
EA201291154A1	Eurasian Patent Organization (EAPO)	A1	2013-04-30
EA201291156A1	Eurasian Patent Organization (EAPO)	A1	2013-04-30
EA201291157A1	Eurasian Patent Organization (EAPO)	A1	2013-04-30
CN103118700A	China	A	2013-05-22
EA201291158A1	Eurasian Patent Organization (EAPO)	A1	2013-05-30
JP2013526617A	Japan	A	2013-06-24
JP2013528181A	Japan	A	2013-07-08
JP2013530157A	Japan	A	2013-07-25
JP2013530158A	Japan	A	2013-07-25
KR20130108983A	Republic of Korea	A	2013-10-07
KR20130108984A	Republic of Korea	A	2013-10-07
KR20130108987A	Republic of Korea	A	2013-10-07
KR20130108988A	Republic of Korea	A	2013-10-07
EP2575876A4	European Patent Office (EPO)	A4	2014-03-26
EP2582393A4	European Patent Office (EPO)	A4	2014-04-02
EP2575773A4	European Patent Office (EPO)	A4	2014-06-25
EP2575886A4	European Patent Office (EPO)	A4	2015-02-25
US9066978B2	United States of America	B2	2015-06-30
US2015328309A1	United States of America	A1	2015-11-19
CN102905728B	China	B	2015-11-25
CN105194665A	China	A	2015-12-30
EA023397B1	Eurasian Patent Organization (EAPO)	B1	2016-05-31
EA201500857A1	Eurasian Patent Organization (EAPO)	A1	2016-06-30
BR112012029912A2	Brazil	A2	2016-11-16
AU2011258147B2	Australia	B2	2016-11-17
AU2011258165B2	Australia	B2	2016-11-17
AU2011258156B2	Australia	B2	2016-11-24
AU2011258171B2	Australia	B2	2016-11-24
CN106177940A	China	A	2016-12-07
JP2017008054A	Japan	A	2017-01-12
JP2017008055A	Japan	A	2017-01-12
JP2017014216A	Japan	A	2017-01-19
JP2017014217A	Japan	A	2017-01-19
BR112012029917A2	Brazil	A2	2017-02-21
AU2017201080A1	Australia	A1	2017-03-09
AU2017201082A1	Australia	A1	2017-03-09
AU2017201143A1	Australia	A1	2017-03-09
AU2017201145A1	Australia	A1	2017-03-09
CN107029222A	China	A	2017-08-11
CN107029223A	China	A	2017-08-11
CN107080839A	China	A	2017-08-22
CN107096021A	China	A	2017-08-29
US9764031B2	United States of America	B2	2017-09-19
MX352324B	Mexico	B	2017-11-17
EP2575876B1	European Patent Office (EPO)	B1	2017-12-06
US2018043023A1	United States of America	A1	2018-02-15
DK2575876T3	Denmark	T3	2018-03-12
PT2575876T	Portugal	T	2018-03-26
MX355036B	Mexico	B	2018-04-02
ES2661978T3	Spain	T3	2018-04-04
JP2018052937A	Japan	A	2018-04-05
JP2018052940A	Japan	A	2018-04-05
JP2018065813A	Japan	A	2018-04-26
NO2575876T3	Norway	T3	2018-05-05
JP6324067B2	Japan	B2	2018-05-16
JP6324068B2	Japan	B2	2018-05-23
IL222725A	Israel	A	2018-06-28
IL222725B	Israel	B	2018-06-28
IL260015A	Israel	A	2018-07-31
IL260015D0	Israel	D0	2018-07-31
PL2575876T3	Poland	T3	2018-07-31
JP6367554B2	Japan	B2	2018-08-01
JP6371058B2	Japan	B2	2018-08-15
KR20180099900A	Republic of Korea	A	2018-09-05

Showing 100 of 114

29 legal events, as the office reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code
2019-05-15	Application deemed to be withdrawnWithdrawn18D	18D
2019-04-12	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA	STAA
2017-02-15	First examination report despatched17Q	17Q
2014-06-25	Supplementary search report drawn up and despatchedA4	A4
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-06-25	Information provided on ipc code assigned before grantRIC1	RIC1
2014-03-12	Request for extension of the european patent (deleted)DAX	DAX
2013-11-13	Request for examination filed17P	17P
2013-11-13	Designated contracting states (corrected)RBV	RBV
2013-05-08	Deferred search report published (corrected)R17D	R17D
2013-04-10	Designated contracting statesAK	AK
2013-04-10	Request for extension of the european patentAX	AX
2013-03-08	Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI	PUAI

Synthetic nanocarrier combination vaccines

Abstract

Term

SYNTHETIC NANOCARRIER COMBINATION VACCINES

BACKGROUND OF THE INVENTION

SUMMARY OF THE INVENTION

BRIEF DESCRIPTION OF FIGURES

DEFINITIONS

ZOSTAVAX, GARDASIL, CERVARIX, FLUARIX, FLUVIRIN, FLUZONE,

FLULAVAL, AFLURIA, AGRIFLU, FLUMIST, JE-VAX, IXIARO, M-M-R II,

EXAMPLES

Priority claims9

Members114

Over the term

Events

Numbers

Titles3

Classification

Designated states40

Abstract

Term

SYNTHETIC NANOCARRIER COMBINATION VACCINES

RELATED APPLICATIONS

BACKGROUND OF THE INVENTION

SUMMARY OF THE INVENTION

BRIEF DESCRIPTION OF FIGURES

DEFINITIONS

METHODS OF MAKING AND USING THE INVENTIVE DOSAGE FORMS AND RELATED METHODS

ZOSTAVAX, GARDASIL, CERVARIX, FLUARIX, FLUVIRIN, FLUZONE,

FLULAVAL, AFLURIA, AGRIFLU, FLUMIST, JE-VAX, IXIARO, M-M-R II,

EXAMPLES

Priority claims9

Members114

Over the term

Events

Numbers

Titles3

Classification

Designated states40